TWI296285B - Promoter sequences from wssv immediate early genes and their uses in recombinant dna techniques - Google Patents
Promoter sequences from wssv immediate early genes and their uses in recombinant dna techniques Download PDFInfo
- Publication number
- TWI296285B TWI296285B TW94100625A TW94100625A TWI296285B TW I296285 B TWI296285 B TW I296285B TW 94100625 A TW94100625 A TW 94100625A TW 94100625 A TW94100625 A TW 94100625A TW I296285 B TWI296285 B TW I296285B
- Authority
- TW
- Taiwan
- Prior art keywords
- sequence
- wssv
- gene
- promoter
- inch
- Prior art date
Links
- 108020004511 Recombinant DNA Proteins 0.000 title claims description 8
- 238000000034 method Methods 0.000 title description 17
- 108700002232 Immediate-Early Genes Proteins 0.000 title description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 167
- 210000004027 cell Anatomy 0.000 claims description 133
- 125000003729 nucleotide group Chemical group 0.000 claims description 55
- 239000002773 nucleotide Substances 0.000 claims description 46
- 241000700605 Viruses Species 0.000 claims description 38
- 108020004414 DNA Proteins 0.000 claims description 35
- 230000014509 gene expression Effects 0.000 claims description 35
- 241000238631 Hexapoda Species 0.000 claims description 34
- 150000007523 nucleic acids Chemical group 0.000 claims description 30
- 230000001105 regulatory effect Effects 0.000 claims description 30
- 239000012634 fragment Substances 0.000 claims description 28
- 238000013518 transcription Methods 0.000 claims description 25
- 238000003752 polymerase chain reaction Methods 0.000 claims description 24
- 230000035897 transcription Effects 0.000 claims description 24
- 102000039446 nucleic acids Human genes 0.000 claims description 23
- 108020004707 nucleic acids Proteins 0.000 claims description 23
- 239000013604 expression vector Substances 0.000 claims description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 18
- 230000002441 reversible effect Effects 0.000 claims description 16
- 238000011144 upstream manufacturing Methods 0.000 claims description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 15
- 238000003259 recombinant expression Methods 0.000 claims description 14
- 238000013519 translation Methods 0.000 claims description 13
- 108091026890 Coding region Proteins 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 12
- 229920001184 polypeptide Polymers 0.000 claims description 12
- 230000002538 fungal effect Effects 0.000 claims description 8
- 230000008488 polyadenylation Effects 0.000 claims description 8
- 230000001580 bacterial effect Effects 0.000 claims description 7
- 239000003550 marker Substances 0.000 claims description 7
- 210000005253 yeast cell Anatomy 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 238000005516 engineering process Methods 0.000 claims description 5
- 238000003786 synthesis reaction Methods 0.000 claims description 5
- 241000238424 Crustacea Species 0.000 claims description 4
- 230000027455 binding Effects 0.000 claims description 4
- 108700008625 Reporter Genes Proteins 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 210000005260 human cell Anatomy 0.000 claims description 3
- 238000003780 insertion Methods 0.000 claims description 3
- 230000037431 insertion Effects 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 230000001131 transforming effect Effects 0.000 claims description 3
- 108700028146 Genetic Enhancer Elements Proteins 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 230000005030 transcription termination Effects 0.000 claims description 2
- 241000282376 Panthera tigris Species 0.000 claims 2
- 108700026220 vif Genes Proteins 0.000 claims 2
- 241000239290 Araneae Species 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000001293 nucleolytic effect Effects 0.000 claims 1
- 238000009418 renovation Methods 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 241000696962 White spot syndrome virus Species 0.000 description 108
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 64
- 102000004169 proteins and genes Human genes 0.000 description 34
- 241000238557 Decapoda Species 0.000 description 33
- 210000002706 plastid Anatomy 0.000 description 31
- 238000004458 analytical method Methods 0.000 description 26
- 101150102264 IE gene Proteins 0.000 description 23
- 239000000047 product Substances 0.000 description 22
- 238000002493 microarray Methods 0.000 description 21
- 241000701447 unidentified baculovirus Species 0.000 description 20
- 239000013598 vector Substances 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 238000010240 RT-PCR analysis Methods 0.000 description 18
- 208000015181 infectious disease Diseases 0.000 description 18
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 17
- 230000014616 translation Effects 0.000 description 16
- 108700026244 Open Reading Frames Proteins 0.000 description 14
- 239000002299 complementary DNA Substances 0.000 description 14
- 108091023040 Transcription factor Proteins 0.000 description 13
- 102000040945 Transcription factor Human genes 0.000 description 13
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 12
- 241000241034 Palaemon pugio Species 0.000 description 12
- 238000001890 transfection Methods 0.000 description 12
- 230000003612 virological effect Effects 0.000 description 12
- 101100495846 Autographa californica nuclear polyhedrosis virus CHIA gene Proteins 0.000 description 11
- 101100066648 Escherichia phage T5 D17 gene Proteins 0.000 description 11
- 101100281854 Orgyia pseudotsugata multicapsid polyhedrosis virus GP64 gene Proteins 0.000 description 11
- 230000002103 transcriptional effect Effects 0.000 description 11
- 241000196324 Embryophyta Species 0.000 description 10
- 108700005077 Viral Genes Proteins 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000013641 positive control Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 210000004102 animal cell Anatomy 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 239000013614 RNA sample Substances 0.000 description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 7
- 108700009124 Transcription Initiation Site Proteins 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 230000009466 transformation Effects 0.000 description 7
- 108010085238 Actins Proteins 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- 102000009572 RNA Polymerase II Human genes 0.000 description 6
- 108010009460 RNA Polymerase II Proteins 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000003623 enhancer Substances 0.000 description 6
- 210000001236 prokaryotic cell Anatomy 0.000 description 6
- 210000003802 sputum Anatomy 0.000 description 6
- 102000007469 Actins Human genes 0.000 description 5
- 241000701022 Cytomegalovirus Species 0.000 description 5
- 206010036790 Productive cough Diseases 0.000 description 5
- 108091081024 Start codon Proteins 0.000 description 5
- 108091023045 Untranslated Region Proteins 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 210000003527 eukaryotic cell Anatomy 0.000 description 5
- 238000010353 genetic engineering Methods 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 208000024794 sputum Diseases 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000001052 transient effect Effects 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 241000238421 Arthropoda Species 0.000 description 4
- 244000063299 Bacillus subtilis Species 0.000 description 4
- 235000014469 Bacillus subtilis Nutrition 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 241000206602 Eukaryota Species 0.000 description 4
- 108700026226 TATA Box Proteins 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 238000013528 artificial neural network Methods 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 238000001243 protein synthesis Methods 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 108090000994 Catalytic RNA Proteins 0.000 description 3
- 102000053642 Catalytic RNA Human genes 0.000 description 3
- 108091035707 Consensus sequence Proteins 0.000 description 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 3
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 241000218922 Magnoliophyta Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- VXQQVDCKACIRQG-UHFFFAOYSA-N NNPP Chemical compound NNPP VXQQVDCKACIRQG-UHFFFAOYSA-N 0.000 description 3
- 241000052303 Orgyia pseudotsugata multiple nucleopolyhedrovirus Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229940123573 Protein synthesis inhibitor Drugs 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 108010067390 Viral Proteins Proteins 0.000 description 3
- 244000144974 aquaculture Species 0.000 description 3
- 238000009360 aquaculture Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000003999 initiator Substances 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 229940047124 interferons Drugs 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000000007 protein synthesis inhibitor Substances 0.000 description 3
- 210000001938 protoplast Anatomy 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 108091092562 ribozyme Proteins 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000010474 transient expression Effects 0.000 description 3
- 230000006648 viral gene expression Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108020003589 5' Untranslated Regions Proteins 0.000 description 2
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- 241000450599 DNA viruses Species 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 102100034349 Integrase Human genes 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 241000209510 Liliopsida Species 0.000 description 2
- 108091081548 Palindromic sequence Proteins 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 241000239226 Scorpiones Species 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 241000318927 Shrimp white spot syndrome virus Species 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 108010084455 Zeocin Proteins 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 241001233957 eudicotyledons Species 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000002816 gill Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000010208 microarray analysis Methods 0.000 description 2
- 238000012775 microarray technology Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 102000037983 regulatory factors Human genes 0.000 description 2
- 108091008025 regulatory factors Proteins 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108091092742 A-DNA Proteins 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 241000743339 Agrostis Species 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000238017 Astacoidea Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241001674044 Blattodea Species 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000218645 Cedrus Species 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 229920002430 Fibre-reinforced plastic Polymers 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 101710110377 Immediate early protein IE1 Proteins 0.000 description 1
- 101710205424 Immediate-early protein 1 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 208000008081 Intestinal Fistula Diseases 0.000 description 1
- 102000010638 Kinesin Human genes 0.000 description 1
- 108010063296 Kinesin Proteins 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101710155913 Major envelope protein Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- JEYCTXHKTXCGPB-UHFFFAOYSA-N Methaqualone Chemical compound CC1=CC=CC=C1N1C(=O)C2=CC=CC=C2N=C1C JEYCTXHKTXCGPB-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 241001465803 Orgyia pseudotsugata Species 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241000237503 Pectinidae Species 0.000 description 1
- 241000238550 Penaeidae Species 0.000 description 1
- 241000634212 Penia Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 240000007332 Podocarpus macrophyllus Species 0.000 description 1
- 101710182846 Polyhedrin Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108091028664 Ribonucleotide Chemical group 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241001248010 Scorpaena guttata Species 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000004350 Strabismus Diseases 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 241001467018 Typhis Species 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical group C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000011151 fibre-reinforced plastic Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- -1 isopropyl- Chemical group 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000012177 large-scale sequencing Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 101150019841 penP gene Proteins 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000002336 ribonucleotide Chemical group 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 235000020637 scallop Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 230000006656 viral protein synthesis Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
1296285 九、發明說明: L潑^明所屬技抽^領域】 • 本發明是有關經分離的核苔酸序列,它們是衍生自一 最近被鑑定出的白點症病毒(WSSV)的極早期基因 5 (immediate early gene),而且它們具有啟動子活性以驅動一 標的基因在一非天然的宿主細胞内的轉錄,因而在供生物 技術領域的使用上具有很大的潛力。 【m袖ί】(相關技藝的描述) • 重組型多肽/蛋白質的生產在生物技術的領域中是一 1〇 非常重要的遺傳工程技術。它的基本原理涉及到將一能表 現一所欲基因產物[例如,核酸代酶(ribozymes)和RNA轉錄 物(RNA transcripts)、工業和農業用酵素、治療性蛋白質、 干擾素(interferons)、間白素(interleukins)、激素 (hormones)、生長激素(growth hormones)、抗原性多肽 15 (antigenic polypeptides)、抗體以及類似物]的標的基因 (target gene)選殖至一個適當的載體内,以及隨後將所形成 ® 的重組型載體轉移至一勝任的宿主細胞(competent host cell)中。由此所形成的重組型宿主細胞可於合適的培養條 件下被於培養於一合適的培養基中,並且該標的基因的表 2〇 現可於一適當的時機下被誘導,以便達到大量生產該所欲 的基因產物的目的。 依據遺傳工程領域中的現今知識與技術,大腸桿菌 (心細胞是最被廣泛運用且最為有效的宿主 細胞,並且已有發展出許多類型的質體載體來供宿留於這 1296285 個細菌物種内。該等質體載體通常被建構成具有一誘導性 人工啟動子(artificial promoter)被選殖在位於一標的基因的 上游處,以便能控制該標的基因的表現。一般最常被使用 的人工啟動子包括/ac、吵、_、ire、araBAZ)、儿?/^和丁7 5啟動子,而這些啟動子可藉由異丙基-/5硫代半乳糖哌喃 甘(isopropyl-万-D-thiogalactopyranoside,IPTG)、乳糖 (lactose)、阿拉伯糖(arabinose)的加入、溫度的變化或類似 方式而被誘導(S.C· Makrides ei αΖ· (1996),jRev·, 60: 512-538)。 10 另一方面’ 一被選殖的標的基因若含有一組成性啟動 子(constitutive promoter),它可被直接地選殖至一載體内。 當使用此一標的基因來建構一重組型載體時,通常無須藉 由誘導的方法來引發重組型多肽/蛋白質的生產。 可被用來進行載體轉形(vector transformation)的其他 15 原核細胞(prokaryotic cells)包括,但不限於,衍生自下列的 細胞:其他的細菌物種/屬[諸如枯草桿菌(jgac/ZZws 似以)、黏質沙雷氏桿菌、乳样菌屬 物種(L似π·)、鏈黴菌屬物種(仍⑺m;yCa π·)以 及沙門氏傷寒桿菌0^/η·)]、藍綠蕩 20 、放線菌(AcizViomycWM)等等。 但是,原核細胞並不會,而酵母菌僅有限地進行被表 現的多肽/蛋白質的轉譯後修飾(post-translational modifications),然而高等真核細胞能夠執行通常為蛋白質 的適當功能所必需的複雜的蛋白質修飾。因此,如果轉譯 6 1296285 後修飾是重組型多肽/蛋白質所需要的,可能會更加希望使 用真核細胞(eukaryotic cells)來生產該重組型多肽/蛋白質。 適合用於進行載體轉形的真核細胞包括,例如··真菌 細胞、原生動物細胞(protozoan cells)、植物細胞、昆蟲細 5 胞、動物細胞以及人類細胞。合適的真菌細胞的實例有: 酵母菌細胞,例如麵包酵母菌(Sacc/mramyca 或 嗜甲醇酵母菌CP/c/n_(2 以及克魯維酵母 [諸如乳酸克魯氏酵母(K Mci⑷與馬克斯 克魯維酵母([的細胞。合適的植物細胞是那些 10 衍生自裸子植物(gynosperms)或被子植物(angiosperms) 的,較佳為單子葉植物(monocots)與雙子葉植物(dicots),特 別是作物(crops),而且是衍生自這些植物的根、莖、葉或 分生組織(meristem),並且呈原生質體(protoplasts)或癒合組 織(callus)的形式被培養。合適的昆蟲細胞的實例是果蠅S2 15 細胞以及衍生自秋行軍蟲/rwg/penia)的Sf21細 胞與Sf9細胞等等。合適的動物細胞可以是被培養的細胞或 活體内細胞’較佳為衍生自脊椎動物,更佳為衍生自哺乳 動物’並且是衍生自這些動物的器官或組織(諸如腎臟、肝 臟、肺臟、卵巢、乳房、皮膚、骨骼、血液)。動物細胞的 20 代表例包括:CHO、COS、BHK、HEK-293、HeLa、NIH3T3、 VERO、MDCK、MOLT-4、Jurkat、K562、HepG2等等。 供應用於轉形上面所示的宿主細胞的載體包括那些通 常被使用於遺傳工程技術中的,例如:噬菌體,諸如又噬 菌體;質體,諸如來自大腸桿菌(五· 的質體(包括 7 1296285 pBR322、pBR325、pUC12、pUC13、pQE-30、ρΕΤ12、ΡΕΤ30 等等),來自枯草桿菌的質體(包括pUBllO、pTP5、pci94 等等),用於大腸桿菌和枯草桿菌的穿梭載體(例如 pHY300PLK),以及來自酵母菌的質體(包括pSH19、PSH15 5等等),黏接質體,病毒’包括··昆蟲病毒,例如桿狀病毒 (baculoviruses);動物病毒,例如牛痘病毒(vaccinia viruses)、巨細胞病毒(cytomegalovirus,CMV)、反轉錄病毒 (retroviruses)等等0 ^ 為達成一選定的標的基因的一個有效表現,希望能構 10 築一含有一有功能的啟動子/調節序列的載體,而該有功能 的啟動子/調節序列被可操作地連結至一為該載體所攜帶 的標的基因。此(等)啟動子/調節序列可以衍生自下列任何 一個:病毒、細菌細胞、酵母菌細胞、真菌細胞、藻類細 胞(algal cells)、植物細胞、昆蟲細胞、動物細胞與人類細 15 胞。例如:一種可用於大腸桿菌(五·⑺/〇細胞的啟動子包 括,但不限於··如c啟動子、T5啟動子、T7啟動子、T7 A1 _ 故動子、lac敗動子、trp故動子、trc敗動子、recA故動子、1296285 IX. INSTRUCTIONS: L P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P 5 (immediate early genes), and they have promoter activity to drive transcription of a target gene in a non-native host cell, thus having great potential for use in the field of biotechnology. [m sleeve] (Description of related techniques) • The production of recombinant peptides/proteins is a very important genetic engineering technique in the field of biotechnology. Its basic principles involve the ability to express a desired gene product [eg, ribozymes and RNA transcripts, industrial and agricultural enzymes, therapeutic proteins, interferons, inter The target genes of interleukins, hormones, growth hormones, antigenic polypeptides, antibodies, and analogs are selected into a suitable vector, and subsequently The recombinant vector formed is transferred into a competent host cell. The recombinant host cell thus formed can be cultured in a suitable medium under suitable culture conditions, and Table 2 of the target gene can be induced at an appropriate timing to achieve mass production. The purpose of the desired gene product. According to current knowledge and technology in the field of genetic engineering, E. coli (heart cells are the most widely used and most effective host cells, and many types of plastid vectors have been developed for retention in these 1,296,285 bacterial species. The plastid vectors are typically constructed to have an inducible artificial promoter that is selected upstream of a target gene to control the performance of the target gene. The most commonly used artificial start The sub-promoter includes /ac, noisy, _, ire, araBAZ), children?/^ and butyl 7 5 promoters, and these promoters can be obtained by isopropyl-/5 thiogalactophosphate (isopropyl-million- D-thiogalactopyranoside, IPTG), lactose, arabinose, temperature change or the like is induced (SC Makrides ei αΖ· (1996), jRev., 60: 512-538). 10 On the other hand, if a selected target gene contains a constitutive promoter, it can be directly colonized into a vector. When using this target gene to construct a recombinant vector, it is usually not necessary to induce the production of recombinant polypeptide/protein by induction. Other 15 prokaryotic cells that can be used for vector transformation include, but are not limited to, cells derived from: other bacterial species/genus [such as Bacillus subtilis (jgac/ZZws) , Serratia marcescens, Lactobacillus species (L like π ·), Streptomyces species (still (7) m; yCa π ·) and Salmonella typhimurium 0 ^ / η ·)], blue green swing 20 Actinomycetes (AcizViomycWM) and so on. However, prokaryotic cells do not, and yeast only performs limited post-translational modifications of the expressed polypeptide/protein, whereas higher eukaryotes are capable of performing the complexities normally required for proper functioning of the protein. Protein modification. Thus, if translation 6 1296285 post-modification is required for recombinant polypeptide/protein, it may be more desirable to use eukaryotic cells to produce the recombinant polypeptide/protein. Eukaryotic cells suitable for use in vector transformation include, for example, fungal cells, protozoan cells, plant cells, insect cells, animal cells, and human cells. Examples of suitable fungal cells are: yeast cells, such as baker's yeast (Sacc/mramyca or methanolic yeast CP/c/n_(2) and Kluyveromyces [such as K. lactis (K Mci (4) and Marks Rude yeast ([ cells. Suitable plant cells are those derived from gynosperms or angiosperms, preferably monocots and dicots, especially crops). (crops), and is derived from the roots, stems, leaves or meristems of these plants, and is cultured in the form of protoplasts or callus. Examples of suitable insect cells are fruit. Fly S2 15 cells and Sf21 cells derived from S. cerevisiae/rwg/penia), Sf9 cells, etc. Suitable animal cells may be cultured cells or cells in vivo 'preferably derived from vertebrates, more preferably Derived from mammals' and is an organ or tissue derived from these animals (such as kidney, liver, lung, ovary, breast, skin, bone, blood). 20 representative samples of animal cells : CHO, COS, BHK, HEK-293, HeLa, NIH3T3, VERO, MDCK, MOLT-4, Jurkat, K562, HepG2, etc. Carriers for the transformation of the host cells shown above include those commonly used in In genetic engineering techniques, for example: phage, such as phage; plastids, such as from Escherichia coli (including plastids (including 7 1296285 pBR322, pBR325, pUC12, pUC13, pQE-30, ρΕΤ12, ΡΕΤ30, etc.), Plastids from Bacillus subtilis (including pUBllO, pTP5, pci94, etc.), shuttle vectors for Escherichia coli and Bacillus subtilis (eg pHY300PLK), and plastids from yeast (including pSH19, PSH15 5, etc.), sticky The plastid, the virus 'including · insect viruses, such as baculoviruses; animal viruses, such as vaccinia viruses, cytomegalovirus (CMV), retroviruses, etc. 0 ^ In order to achieve an effective expression of a selected target gene, it is desirable to construct a vector containing a functional promoter/regulatory sequence, and the functional promoter/tune The sequence is operably linked to a target gene carried by the vector. The (etc.) promoter/regulatory sequence can be derived from any of the following: viruses, bacterial cells, yeast cells, fungal cells, algal cells (algal cells) ), plant cells, insect cells, animal cells, and human fine cells. For example, a promoter that can be used in E. coli (five (7)/〇 cells includes, but is not limited to, such as c promoter, T5 promoter, T7 promoter, T7 A1 _ actor, lac neutron, trp Therefore, the mover, trc loser, recA, mover,
Zpp啟動子、arajBAD啟動子以及;I 啟動子。一種可用 於桿菌屬物種細胞的啟動子包括,但不限於:SP01啟動 20 子、SP0啟動子、penP啟動子等等。一種可用於酵母菌細 胞的啟動子包括,但不限於:PH05啟動子、PGK啟動子、 GAP啟動子、ADH啟動子等等。一種可用於昆蟲細胞的啟 動子包括,但不限於:多角體蛋白(polyhedrin)啟動子、p10 啟動子、〇pIE2 (OpMNPV 啟動子等等。一種可用於動 8 1296285 物細胞的啟動子包括,但不限於:SRα啟動子、SV40早期 啟動子、RSV-啟動子、HIV-LTR啟動子、HSV-TK啟動子、 CMV啟動子、CMV-HSV胸苷激酶(thymidine kinase)啟動子 等等。一種可用於植物細胞的啟動子包括,例如:35S CaMV 5 啟動子、肌動蛋白(actin)啟動子、泛素(ubiquitin)啟動子等 等。適合供應用於嗔乳動物細胞的調節要素(regUlat〇ry elements)包括:CMV-HSV胸苷激酶啟動子、SV40早期啟動 子、RSV-啟動子、CMV增強子以及SV40增強子。 ® 另外,代表性的RNA聚合酶啟動子可被分類成下面的 10 類型:誘導性啟動子、組成性啟動子、組織專一性啟動子 以及合成的啟動子。代表性的誘導性啟動子是:熱誘導性 Hsp70啟動子、一種金屬硫蛋白(metaii〇thi〇nein)啟動子、一 種醇脫氫酶(alcohol dehydrogenase)啟動子以及一種半乳糖 (galactose)啟動子。代表性的組成性啟動子是勞氏肉瘤病毒 I5 (Rous sarcoma virus,RSV) LTR啟動子、人類巨細胞病毒 (CMV)主要極早期基因啟動子以及Sv4〇早期啟動子;以及 ® 代表性的組織專一性啟動子是一種阿爾發血紅素(alpha globm)啟動子與一種貝他血紅素(betaglobin)啟動子。合成 的啟動子可以藉由化學地或重組地修飾天然的啟動子而被 20 生成。 除了缺乏轉譯後修飾機轉之外,存在有其他的與在原 核細胞内表現某些蛋白質有關聯的問題。例如,某些被表 現的異源性蛋白(heterolog〇Us pr〇teins)是有如不溶性包涵 體被儲存在原核細胞内,而使該等蛋白質的回收變得困 9 1296285 難。許多與原核表現系統有關聯的困難可以藉由使用經轉 形的哺乳動物細胞培養系統來生產被轉譯後加工的蛋白質 (post-translationally processed proteins)而被克服0 然而,哺 乳動物細胞培養物可能相對地較不有效,因為它們生長緩 5 慢以及在維持上較困難且花費較高。 在昆蟲細胞的培養上的進步,以及以桿狀病毒為主的 表現系統之發展,已經促進異源性蛋白質藉由經轉形的昆 蟲細胞株的表現(Lwcbw Swmmers (7988),iB/cvTec/i·,(5, 47-55·,Miller (1988),Annu· Rev· Microbiol·,42, 177-199)。良 10今,異源性蛋白質在經轉形的昆蟲細胞株内的表現主要是 使用衍生自桿狀病毒苜蓿尺蠖核多角體病毒 californica multicapsid nucleopolyhedrosis virus, AcMNPM)(Luckow and Summers (1988),如上述;Miller (79SSJ,如2遂)的載體而被完成。 15 桿狀病毒是雙股的DNA病毒,它們是藉由在一典型的 感染週期之後的溶胞作用(lySis)來殺死被感染的昆蟲細 胞。已知有各種不同的桿狀病毒,它們各個對於一種特定 的節肢動物物種(arthropod species)是特有的。尚不知桿狀 病毒是否可在節肢動物門以外的動物體内進行複製。 20 在一昆蟲的天然的桿狀病毒感染期間當中的基因表現Zpp promoter, arajBAD promoter and; I promoter. A promoter useful for cells of the genus Bacillus includes, but is not limited to, SP01 promoter 20, SP0 promoter, penP promoter, and the like. A promoter useful for yeast cells includes, but is not limited to, a PH05 promoter, a PGK promoter, a GAP promoter, an ADH promoter, and the like. A promoter useful for insect cells includes, but is not limited to, a polyhedrin promoter, a p10 promoter, a 〇pIE2 (OpMNPV promoter, etc.) a promoter that can be used to mobilize cells of 8 1296285, but Not limited to: SRα promoter, SV40 early promoter, RSV-promoter, HIV-LTR promoter, HSV-TK promoter, CMV promoter, CMV-HSV thymidine kinase promoter, etc. One is available Promoters for plant cells include, for example, a 35S CaMV 5 promoter, an actin promoter, a ubiquitin promoter, etc. Suitable for supplying regulatory elements for sputum animal cells (regUlat〇ry) Elements) include: CMV-HSV thymidine kinase promoter, SV40 early promoter, RSV-promoter, CMV enhancer, and SV40 enhancer. In addition, representative RNA polymerase promoters can be classified into the following 10 types. : an inducible promoter, a constitutive promoter, a tissue-specific promoter, and a synthetic promoter. Representative inducible promoters are: a heat-inducible Hsp70 promoter, a metallothionein (me Taii〇thi〇nein) promoter, an alcohol dehydrogenase promoter and a galactose promoter. A representative constitutive promoter is Rous sarcoma virus (RSV). LTR promoter, human cytomegalovirus (CMV) major very early gene promoter and Sv4〇 early promoter; and ® representative tissue-specific promoter is an alpha globm promoter and a beta The betaglobin promoter. The synthetic promoter can be produced by chemically or recombinantly modifying the native promoter. In addition to the lack of post-translational modification, there are other and expressed in prokaryotic cells. Some proteins have associated problems. For example, some heterologous proteins (heterolog〇Us pr〇teins) are expressed as insoluble inclusion bodies are stored in prokaryotic cells, which makes the recovery of such proteins sleepy. 1296285 Difficulties. Many of the difficulties associated with prokaryotic expression systems can be produced by translating mammalian cell culture systems. Post-translationally processed proteins are overcome. However, mammalian cell cultures may be relatively less effective because they are slower to grow and more difficult to maintain and costly. Advances, as well as the development of baculovirus-based expression systems, have promoted the expression of heterologous proteins by transduced insect cell lines (Lwcbw Swmmers (7988), iB/cvTec/i·, (5, 47) -55·, Miller (1988), Annu· Rev·Microbiol·, 42, 177-199). In the case of transgenic insect cell lines, the heterologous protein is mainly derived from the bacillus virus californica multicapsid nucleopolyhedrosis virus (AcMNPM) (Luckow and Summers (1988), as described above The Miller (79SSJ, eg 2遂) vector is completed. 15 Baculoviruses are double-stranded DNA viruses that kill infected by lysis (lySis) after a typical infection cycle. Insect cells. A variety of different baculoviruses are known, each of which is unique to a particular arthropod species. It is not known whether baculovirus can replicate in animals other than arthropods. Gene expression during an insect's natural baculovirus infection
被南度0周控並且有如一有順序的級聯(〇r(JerecJ cascacje)來發 生。病毒基因可以依據它們在這個基因表現的級聯内的位 置而被分類成四個不同的類別··極早期(IE)、遲發早期 (DE)、晚期以及與非常晚期。早期基因表現發生在病毒dnA 1296285 複製的開始之前,並且似乎是晚期病毒基因表現的誘導所 必要的(Blissczrd and Rohnnann (1990),Amm· Rev· Entomol” 35: 127-155·,Guarino and Summers (1988),J· Virol 62 * 463-471·,Miller et al· (1983),Virology,126·· 376-380、。實驗 5證據顯示出·在無其他病毒因子的存在下,桿狀病毒^基因 是由宿主的RNA聚合峰Π所轉錄。因此知道桿狀病毒化基因 具有可被宿主細胞的轉錄機制所辨識的啟動子。 上面有關於才干狀病毋及其化基因的描述是引述自us 20020116723 A1,該案揭露使用衍生自一桿狀病毒極早期 10啟動子的啟動子來控制一可選擇的標記基因的表現,該標 記基因提供針對博萊黴素/腐草黴素型抗生素 (bleomycin/phleomycin-type antibiotics)的家族當中一個的 抗性。特別地,US 20020116723 A1揭露:衍生自黃杉毒 蛾核多角體病毒(0客>^ «料姒multicapsid 15 nucleopolyhedrosis virus, OpMNPV)的ie/和z>2基因的和 化2啟動子可以被可操作地連結至一可選擇的標記基因以便 控制自該可選擇的標記基因的轉錄作用,並且該可選擇的 標記基因可以是會對昆蟲細胞提供Zeocin抗性的印度斯坦 鍵異壁菌⑽//〇如Me基因。 2〇 描述病毒載體和/或含有病毒啟動子的載體的構築的 專利以及被公開的專利申請案包括,但不限於:US 5,077,214、US 5,162,222、US 5,168,062、US 5,385,839、 US 20020116723A卜 US 20030108524A1、US 20030108863It is controlled by Southern 0 weeks and has a sequence of cascades (JerecJ cascacje). Viral genes can be classified into four different categories based on their position within the cascade of genes. Very early (IE), late onset (DE), late, and very late. Early gene expression occurred before the onset of viral dnA 1296285 replication and appeared to be necessary for induction of late viral gene expression (Blissczrd and Rohnnann (1990) ), Amm· Rev· Entomol 35: 127-155·, Guarino and Summers (1988), J. Virol 62 * 463-471·, Miller et al. (1983), Virology, 126·376-380. The experimental 5 evidence shows that in the absence of other viral factors, the baculovirus gene is transcribed by the host RNA RNA peak. Therefore, it is known that the baculovirus gene has a promoter that can be recognized by the transcription mechanism of the host cell. The above description of the genital pathogen and its genes is quoted from us 20020116723 A1, which discloses the use of a promoter derived from a very baculovirus very early 10 promoter to control a selectable marker. Due to the performance, the marker gene provides resistance to one of the families of bleomycin/phleomycin-type antibiotics. In particular, US 20020116723 A1 discloses: derived from the genus of cedar moth Polyhedrosis virus (0 </ br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br> The transcription of the marker gene can be selected, and the selectable marker gene can be a Shigella bentgrass (10)//such as a Me gene that provides Zeocin resistance to insect cells. 2. Describe the viral vector and/or contain Patents for the construction of vectors for viral promoters and published patent applications include, but are not limited to, US 5,077,214, US 5,162,222, US 5,168,062, US 5,385,839, US 20020116723A, US 20030108524A1, US 20030108863
Al、US 20030229046 Al、US 20040082531 Al、US 11 1296285 20040161841 A1、US 20040197313 A1、WO 99/61636 A1 以 及WO 0105992 A1。 與用於構築可應用於宿主細胞的轉形(transformation) 和/或轉染(transfection)的載體的病毒啟動子和/或調節序列 5 的鑑定相關的文獻參考資料包括,但不限於:r〇m A.Al, US 20030229046 Al, US 20040082531 Al, US 11 1296285 20040161841 A1, US 20040197313 A1, WO 99/61636 A1 and WO 0105992 A1. Literature references related to the identification of viral promoters and/or regulatory sequences 5 for constructing vectors for transformation and/or transfection applicable to host cells include, but are not limited to: r〇 m A.
et al· (1997),Gene,188,183-190·,Steven S. Pullen and Paul D· Friesen,June 1995,69 (6),3575-3583·,Fan Xiu Zhu et al·, J· Virol” July 1999,73 (7),5556-5567·,R.L· Harrison and B.C· Bonning (2003),J· Gen· Virol·,84 (Pt 7),1827-1842·, 10 Ε·Β· Carstens et al·,Virus research (2002),83,13-30\ Μ·Κ· Barnhart et al·,J· Virol·,Jan· 1997,71 (1),337-344\ LA· Guarino and M.D· Summers,J· Virol” Feb· 1986,57 (2), 563-571\ V.A. Olson et al, J. Viroly May 2003, 77 (10), 5668-5677·,Ε·Α· van Strien et al·,Arch Virol· (2000),145, 15 2115-2133、VA· Olson et al” J. Virol” Sep· 2002,76 (18), 9505-9515·,Andrew K· Cheung (1999),Nucleic Acid Research, 17 (12), 4637-4646; Alexandra Garcia-Maruniak et al.,J· Virol·,July 2004, 78 (13),7036-7051·,K· Kojima et al. (2001),Arch Virol·,146, 1407-1414 〇 20 雖然如上所述,本技藝中的研究人員仍然致力於探究 任何有潛力的啟動子和/或調節序列,它們可被用於構築可 應用在重組型多肽/蛋白質的生產的重組型表現載體。 白點症病毒(white spot syndrome virus WSSV)或白點 桿狀病毒(white spot bacilliform virus,WSBV),它是一種有 12 1296285 外套的橢圓體狀大型雙股DNA病毒,是全世界的養殖蝦類 的最毒且最危險的病毒性病原當中的一個([/nowK以αΖ·, Fish Pathol· (1994),29:149-158认 S^Fish Pathol· (1996),31: 39-45\ Nakano et al·,Fish Pathol· (1994),29 (2):135-139\ 5 Takahashi et al” Fish Pathol· (1994),29 (2): 121-125’,Η·-Υ· Chou et al· (1995),Dis· Aquat· Org·,23:165-173·,J· Huang et aLy Marine Fish Res. (1995), 16:1-10 and Marine Fish Res. (1995),16:11-23; C.-F· Lo,et al·,Dis· Aquat· Org· (1996), 27,215-225以反J· Fish· Soc, Taiwan (2003),30,1-13·,C,H. 10 Wang et al. (1995), Dis Aquat. Org., 23:239-242; C. Wongteerasupaya et al· (1995),Dis· Aquat· Org·,21:69-77·, T.W· Flegel (1997),World J. Microbiol. Biotech·,13, 433-442·,Y· Lu et al· (1997),J. Gen· Virol” 84:1517-1523、。 它也會攻擊許多其他的甲殼類(crustaceans),諸如蟹類 15 (crabs)和螯蝦(crayfishes)。另外,由於WSSV的獨特性,要 藉由直接地應用其他病毒的感染模式來解釋WSSV的感染 策略是困難的。結果,WSSV的感染策略可能必須從頭開始 研究。 形態上,WSSV的病毒粒子(virion)是一大約為275x120 20 nm並且具有一撖視至桿狀的形狀的非封埋性有外套的顆粒 體(nonoccluded,enveloped particle),並且具有一帶有垂直 於長軸的週期性條紋的核殼體(3〇〇X7〇 nm)(d 以 aL (J995), Dis Aquat Org·, 23: 239-242·, C.Et al. (1997), Gene, 188, 183-190·, Steven S. Pullen and Paul D. Friesen, June 1995, 69 (6), 3575-3583·, Fan Xiu Zhu et al·, J· Virol” July 1999, 73 (7), 5556-5567·, RL· Harrison and BC· Bonning (2003), J. Gen·Virol·, 84 (Pt 7), 1827-1842·, 10 Ε·Β· Carstens et al ·, Virus research (2002), 83, 13-30\Μ·Κ· Barnhart et al·, J. Virol·, Jan·1997, 71 (1), 337-344\LA· Guarino and MD· Summers, J · Virol” Feb· 1986, 57 (2), 563-571\ VA Olson et al, J. Viroly May 2003, 77 (10), 5668-5677·, Ε·Α·van Strien et al·, Arch Virol· (2000), 145, 15 2115-2133, VA· Olson et al” J. Virol” Sep. 2002, 76 (18), 9505-9515·, Andrew K. Cheung (1999), Nucleic Acid Research, 17 (12 ), 4637-4646; Alexandra Garcia-Maruniak et al., J. Virol, July 2004, 78 (13), 7036-7051·, K. Kojima et al. (2001), Arch Virol·, 146, 1407- 1414 〇20 Although as mentioned above, the researchers in this art are still committed to exploring any potential Promoter and / or regulatory sequences, they may be used for constructing recombinant can be used in the production of a recombinant polypeptide / protein expression vector. White spot syndrome virus (WSSV) or white spot bacilliform virus (WSBV), an elliptical large double-stranded DNA virus with 12 1296285 coat, is a cultured shrimp in the world. One of the most toxic and dangerous viral pathogens ([/nowK by αΖ·, Fish Pathol· (1994), 29:149-158 recognizes S^Fish Pathol· (1996), 31: 39-45\ Nakano Et al., Fish Pathol· (1994), 29 (2): 135-139\ 5 Takahashi et al” Fish Pathol· (1994), 29 (2): 121-125', Η·-Υ·Chou et al · (1995), Dis· Aquat· Org·, 23: 165-173·, J. Huang et aLy Marine Fish Res. (1995), 16:1-10 and Marine Fish Res. (1995), 16:11- 23; C.-F· Lo, et al·, Dis· Aquat· Org· (1996), 27, 215-225 to anti-J·Fish·Soc, Taiwan (2003), 30, 1-13·, C, H. 10 Wang et al. (1995), Dis Aquat. Org., 23:239-242; C. Wongteerasupaya et al. (1995), Dis· Aquat· Org·, 21:69-77·, TW· Flegel (1997), World J. Microbiol. Biotech·, 13, 433-442·, Y·Lu et al· (1997), J. Gen· Virol” 84: 1517-1523, it also attacks many other crustaceans, such as crabs and crayfishes. In addition, due to the uniqueness of WSSV, it is necessary to directly apply infections of other viruses. Modes to explain WSSV infection strategies are difficult. As a result, WSSV infection strategies may have to be studied from scratch. Morphologically, WSSV virions are about 275x120 20 nm and have a squint-to-rod shape. Non-embedded has nonoccluded, enveloped particles and has a nucleus shell with periodic fringes perpendicular to the long axis (3〇〇X7〇nm) (d in aL (J995), Dis Aquat Org·, 23: 239-242·, C.
Wongteerasupaya et al (1995),Dis· Aquat· Org,,21: 13 1296285 仍-77)。WSSV的最顯著特徵是在病毒粒子的一端處存在有 一尾狀的延伸部分(肠叩(7995),如2遂; S· Durand et al· (1997),Dis. Aquat· Org·,29:205-211) 〇 完整基因組定序(genome sequencing)已在3種WSSV分 5 離株上被執行(關於台灣分離株WSSV T-l,參見NCBI登錄 編號AF440570 ;關於泰國分離株,參見NCBI登錄編號 AF369029 ;以及關於中國分離株,參見NCBI登錄編號 AF332093)。WSSV基因組(〜300 kb)比長囊水雲病毒 [五cioarp⑽hZ/cw/omy virus,EsV-1,藻去氧核糖核酸病毒 10 科(PA;ycW⑽v/r/也^)]的335,593 bp基因組要小〜30 kb,長囊 水雲病毒是迄今已被定序的最大病毒基因組(/.L. van Etten et al· (2002),Arch Virol” 147,1479-516、。 針對個別基因的先前研究以及完整的基因組序列的分 析暗示WSSV不屬於任何已知的病毒科乃⑴· ei β/., 15 Virology (2000), 277, 92-99 and Virology (2000), 277:100-110; W.J· Liu et al”(2001),Virology 289: 362-377·, Feng Yang et al·,J· Virol” Dec. 2001,75 (23): 11811-11820·, C.W. Marielle et aL, Virology. July 20, 2001, 286 (l):7-22\ L.-L. Chen et al· (2002),Virology 301: 136-147·,H. Marks et 20 al· (2003),J Gen Viwl 84:1517-1523)。最近,WSSV被提議 是歸屬於線病毒科的白點病毒屬(Μπ·v/rws) 的典型物種(type species)(M.i4· Mfl;yo (2002J,Arc/t· Vz><9/·, 147, 1655-1663)。 在申請人針對台灣分離株使用微陣列技術(microarray 14 1296285 technique)的較早基因組分析中,這個分離株被鑑定出具有 總共532個推定的開放讀取架構(0pen reading frame, 〇RF),它們是以一個ATG起始密碼子來開始並且可能編碼 一為至少60個胺基酸長的多肽,在這些〇RF當中,迄今已 5有39個被鑑定出是WSSV結構基因以及有少於12個是非結 構基因。另外,對於〜90%的這些ORF已偵測到有轉錄本 (transcripts)^.-C. Wang, et aL UDNA microarrays of the white spot syndrome virus genome: genes expressed in the gidls of infected shrimp,” Marine Biotechnology,付特中)〇 男 10 外’根據針對NCBInr資料庫的同源性搜尋(homology searches),就該台灣分離株而被公佈的大多數ORF與其他已 知的蛋白質顯示出沒有顯著的相似性。關於其他雨種分離 株有相似的結果被報導(Μαη·έ7& C.W· van 以αΖ·,Wongteerasupaya et al (1995), Dis· Aquat· Org,, 21: 13 1296285 still-77). The most striking feature of WSSV is the presence of a caudal extension at one end of the virion (intestinal fistula (7995), such as 2遂; S· Durand et al. (1997), Dis. Aquat· Org·, 29:205 -211) 〇 complete genome sequencing has been performed on 3 WSSV sub- 5 isolates (for Taiwan isolate WSSV Tl, see NCBI accession number AF440570; for Thai isolates, see NCBI accession number AF369029; and For Chinese isolates, see NCBI Accession No. AF332093). The WSSV genome (~300 kb) is smaller than the 335,593 bp genome of the long-sac water cloud virus [five cioarp(10)hZ/cw/omy virus, EsV-1, algae deoxyribonucleic acid 10 (PA; ycW(10)v/r/also ^)] ~30 kb, long-sac water cloud virus is the largest viral genome that has been sequenced to date (/.L. van Etten et al. (2002), Arch Virol" 147, 1479-516. Previous studies on individual genes and complete Analysis of the genomic sequence suggests that WSSV does not belong to any known virus (1)·ei β/., 15 Virology (2000), 277, 92-99 and Virology (2000), 277:100-110; WJ· Liu et Al" (2001), Virology 289: 362-377·, Feng Yang et al., J. Virol" Dec. 2001, 75 (23): 11811-11820·, CW Marielle et aL, Virology. July 20, 2001, 286 (l): 7-22\ L.-L. Chen et al. (2002), Virology 301: 136-147·, H. Marks et 20 al· (2003), J Gen Viwl 84:1517-1523) Recently, WSSV has been proposed to be a type species belonging to the genus Plasmodium (Μπ·v/rws) of the genus Line Virus (M.i4·Mfl;yo (2002J, Arc/t·Vz><> 9/·, 147, 1655-1663). In Shen In an earlier genomic analysis of human microarray technology using the microarray technique (microarray 14 1296285 technique), this isolate was identified as having a total of 532 putative open reading frames (〇RF), which are An ATG start codon begins and may encode a polypeptide of at least 60 amino acids long. Of these 〇RFs, 39 have been identified as WSSV structural genes and less than 12 are non-structural In addition, for ~90% of these ORFs have been detected transcripts ^.-C. Wang, et aL UDNA microarrays of the white spot syndrome virus genome: genes expressed in the gidls of infected shrimp," Marine Biotechnology, Fu Tezhong) 〇男10's According to the homology searches for the NCBInr database, most of the ORFs published for this Taiwan isolate showed no significant difference with other known proteins. Similarity. Similar results have been reported for other rain species isolates (Μαη·έ7& C.W·van with αΖ·,
Virology· July 20,2001,286 (l):7-22; Feng Yang et al” J. 15 Viwl” Dec· 2001,75 (23)·· 11811-11820、〇 然而,雖然WSSV基因的暫時性表現已藉由個別的基因 研究(L,L· Chen et al· (2002),Virology,301,136-147·,J.-H· Leu,et al· (2005),J· Virol” Jan· 2005, 79 (1),140,149.,W.-J· Liu,et al. (2001),Virology 289, 362-377·,M.-F· Tsai et al·, 20 Virology (2000), 277, 92-99 and Virology 277 {2000), 川以及藉由總體性分析(从上乃以以以(200句,乂 Virol· 78, 11360-11370·,H,C· Wang et al·,“DNA microarrays of the white spot syndrome virus genome: genes expressed in the gills of infected shrimp,” Marine Biotechnology,竹梓中、 15 1296285 而被探討,迄今,沒有WSSV極早期(IE)基因被鑑定出。 從文獻而注意到的,病毒IE基因的表現會視宿主細胞 機制而定,且不涉及任何病毒的從頭蛋白質合成(A novo protein synthesis)而發生,這表示該等IE基因在決定宿主範 5 圍上是格外重要的(P.D· Friesen (1997),“心抑/如·⑽< Baculovirus early gene expression^ In: Miller, L.K., (Ed.), The baculoviruses. Plenum Press, New York and London, pp. 141-170)。該等IE基因產物,一旦被表現,在感染期間可以 產生有如調節性反式-作用因子(regulatory trans-acting 10 factors)的功能以及可以用來起始病毒的複製事件。在病毒 的調節事件的級聯中,病毒複製的連續階段要依靠位於前 一個階段内的基因的適當表現。例如,在諸如桿狀病毒 (baculoviruses)和泡療病毒(herpesviruses)大型 DNA病毒所 致的感染期間當中,基因表現被調控而使得極早期(IE或α ) 15 基因首先被轉錄,繼而分別為早期(Ε或/3)與晚期(L或τΟ 基因的表現(G. W. 口99(5J,C;yi(9iec/m(9/(9g;y,2(9, 73-93; G.W· Blissard and G.F· Rohrmann (1990),Annu· Rev· Entomol·,35,127-155、P.D· Friesen and L.K Miller (1986), Curr. Top. Microbiol Immunol. 131 f 31-49; R.W. Honess and 20 B. Roizman (1974),J. Virol·,14, 8-19、。 為了研究病毒IE基因的轉錄,病毒感染是在一種藉由 阻止轉譯而防止從頭蛋白質合成的蛋白質合成抑制劑[通 常是放射菌酮(cycloheximide,CHX)]的存在下被誘發。假使 IE基因的轉譯(而非轉錄)被遏阻,病毒的感染週期同樣會被 16 1296285 阻遏在IE階段。因此,在CHX的恆定存在下,在病毒感染 期間被偵測到的RNA轉錄本的存在是用於鏗定病毒正基因 的良好證據。 在此第一次,儘管缺乏任何被公認的永生不死的蝦細 5胞株以及在活體内使用CHX有困難,申請人成功地使用 CHX作為一抑制劑來阻遏病毒的從頭蛋白質合成。一種總 體性分析微陣列技術與反轉錄酶聚合酶連鎖反應(RT—PCR) 隨後被使用以決定WSSV的轉錄態樣(transcription pattern),從這所得到的結果,3個—”極早期⑽基因候 10送物被鑑疋出並被命名為、化2和化3。另外,從該wgjsv 基因被選殖(cloned)出的啟動子·調節區域被證實在非天 然的宿主細胞(亦即Sf9昆蟲細胞)内具有啟動子活性,因而 在供重組DNA技術領域的應用上具有極大的潛力。 C發明内容]J 15 發明概要 因此’依據第-個方面,本發明提供一種經分離的 WSSV極早期啟動子·調節區域,它基本上是由一選自於下 列群組中的核苷酸序列所構成: ⑴為序列辨識編號:29的核g酸序列; (11)為⑴的才玄苔酸序列的5、戴短的片段(5,-truncated fragment),[具有切顺識編號:洲〗,端算起 的至少92個核笞酸殘基; ⑽核酉夂序列,它是由使用-白點症病毒(WSSV)基 因組DNA作為模板以及—具有〆順向引子與一反 17 1296285 向引子的引子組的聚合酶連鎖反應(polymerase chain reaction)而被擴增出,該順向引子基本上是由 一選自於如序列辨識編號:15與序列辨識編號:π 所示的核苷酸序列當中的核苷酸序列所構成,而該 5 反向引子基本上是由一為序列辨識編號:16的核苔 酸序列所構成;Virology· July 20, 2001, 286 (l): 7-22; Feng Yang et al” J. 15 Viwl” Dec· 2001, 75 (23)·· 11811-11820, however, although the temporary performance of the WSSV gene Already by individual genetic studies (L, L. Chen et al. (2002), Virology, 301, 136-147·, J.-H. Leu, et al. (2005), J. Virol” Jan. 2005 , 79 (1), 140, 149., W.-J. Liu, et al. (2001), Virology 289, 362-377·, M.-F· Tsai et al·, 20 Virology (2000), 277 , 92-99 and Virology 277 (2000), Sichuan and by total analysis (from the above to (200 sentences, 乂Virol 78, 11360-11370·, H, C· Wang et al, “DNA Microarrays of the white spot syndrome virus genome: genes expressed in the gills of infected shrimp," Marine Biotechnology, P. chinensis, 15 1296285 was explored, and so far, no WSSV very early (IE) genes have been identified. As a result, the expression of the viral IE gene will depend on the host cell mechanism and does not involve any virus a novo protein synthesis, which means that the IE group It is particularly important to determine the host range (PD·Friesen (1997), “heart suppression/如·(10)< Baculovirus early gene expression^ In: Miller, LK, (Ed.), The baculoviruses. Plenum Press, New York and London, pp. 141-170). These IE gene products, once expressed, can produce functions such as regulatory trans-acting 10 factors during infection and can be used to initiate Replication events of viruses. In the cascade of regulatory events of the virus, the successive stages of viral replication rely on the proper expression of genes located in the previous phase, for example, in baculoviruses and herpesviruses. During the infection period caused by large DNA viruses, gene expression is regulated such that the very early (IE or α) 15 genes are first transcribed, followed by early (Ε or /3) and late (L or τΟ gene expression (GW) Mouth 99 (5J, C; yi (9iec/m (9/(9g; y, 2 (9, 73-93; GW· Blissard and GF· Rohrmann (1990), Annu· Rev· Entomol·, 35, 127- 155. PD·Friesen and LK Miller (1986), C Urr. Top. Microbiol Immunol. 131 f 31-49; R.W. Honess and 20 B. Roizman (1974), J. Virol, 14, 8-19. To investigate the transcription of the viral IE gene, viral infection is induced in the presence of a protein synthesis inhibitor [usually cycloheximide (CHX)] that prevents de novo protein synthesis by preventing translation. If the translation of the IE gene (rather than transcription) is blocked, the viral infection cycle will also be repressed by the IE phase in 16 1296285. Thus, in the constant presence of CHX, the presence of RNA transcripts detected during viral infection is a good evidence for identifying positive viral genes. For the first time, despite the lack of any recognized immortal shrimp cell line and the difficulty of using CHX in vivo, Applicants successfully used CHX as an inhibitor to deter virus de novo protein synthesis. A total analysis of microarray technology and reverse transcriptase polymerase chain reaction (RT-PCR) was subsequently used to determine the transcription pattern of WSSV, and the results obtained from this were three "very early (10) genes. The 10th donor was identified and named as 2, and 3. In addition, the promoter-regulated region cloned from the wgjsv gene was confirmed in a non-native host cell (ie, Sf9). The insect cell has promoter activity and thus has great potential for application in the field of recombinant DNA technology. C SUMMARY OF THE INVENTION J 15 SUMMARY OF THE INVENTION [In accordance with the first aspect, the present invention provides an isolated WSSV very early a promoter/regulatory region consisting essentially of a nucleotide sequence selected from the group consisting of: (1) a nuclear g acid sequence of sequence identification number: 29; (11) a sylvestre acid of (1) Sequence 5, short-cut fragment (5,-truncated fragment), [with cut-off number: continent, at least 92 nucleotide residues from the end; (10) nuclear sequence, which is used by - White spot virus (WSSV) genomic DNA The plate and the polymerase chain reaction having a cis- forward primer and a primer 17 1296285 to the primer are amplified, and the forward primer is substantially selected from a sequence identification number : 15 is composed of a nucleotide sequence among nucleotide sequences indicated by SEQ ID NO: π, and the 5 reverse primer is basically composed of a nucleotide acid sequence of sequence identification number: 16;
10 1510 15
(iv) —為⑴的核苷酸序列的核酸類似物(nucieic acid analogue),它與⑴的核苷酸序列具有至少大約6〇% 的序列相同性,並且可以驅動一被可操作地連結 (operatively connected)至該核酸類似物的標的基因 的表現; (v) —為(ii)的5’-截短的片段的核酸類似物,它與⑴)的 5’-截短的片段具有至少大約60%的序列相同性,並 且可以驅動一被可操作地連結至該核酸類似物的 標的基因的表現; (vi) —為⑴的核苷酸序列的變異體(variant),它含有至 少一個守恒性取代(conservative subs_ti〇n),並且 可以驅動一被可操作地連結至該變異體的標的基 因的表現;以及 (VII)—為(ii)的5’-截短的片段的變異體,它含有至少一 個寸恆性取代,並且可以驅動一被可操作地連結至 該變異體的標的基因的表現。 上述的WSSV極早期啟動子,節區域可以觸發一異源 t生基口在非天錢彳§主細胞内的表現,而因此可被用來構 18 1296285 築各種不同的重組型表現載體以供用於轉形—廣泛範圍的 伯主細胞。因此’依據第二個方面,样 現載體,它們被構建成包含有 *,錢表 W基□’以及上述的wssv極早期啟動子調節區域被可 操作地連結至該標的基因。 依據第三個方面,本發明提供重組型宿主細胞,它們 是由以上述的重組型表現載體來轉形宿主細胞而被產生。 10 15 可以預期到本發明的實施並不受限於特定的宿主細胞 的使用。事實上,本發明可被應用至各式各樣的原核與真 核宿主細胞’包括細菌細胞、酵母菌細胞、真菌細胞、植 物細胞、昆蟲細胞、哺乳動物細胞等等,並且可被用來生 產有用的核酶和RNA轉錄物,以及不同類型的蛋白質,包 括:存在於細胞質㈣〇plasm)或近膜間隙(pedpiasmic space) 内的虫白貝、存在於細胞膜(ceu membrane)上的蛋白質或細 胞外的蛋白質,以及可供應用在卫業、農業、食品工業、 兄工業、水產業和畜牧業上的酵素,尤其是醫藥用蛋白 質和胜肽’諸如干擾素、人類和動物激素、免疫性抗原以 及抗體。 依據第四個方面,本發明提供一種用於一 WSSV極早期 20啟動子4周節區域的選殖的引子組,其包含有一順向引子和 一反向引子,該順向引子基本上是由一選自於如序列辨識 編號· 15 (亦即被顯示於實施例中所描述的表2内的引子 126-lk-F)與序列辨識編號:17 (亦即被顯示於實施例中所描 述的表2内的引子i26-2k-F)所示的核苷酸序列的核笞酸序 19 1296285 列所構成,*該反向引子基本上是為相辨識編號: 16 (亦即被顯示於實施例中所描述的表2内的弓丨子126_R)的 核苷酸序列所構成。 圖式簡單說明 5 本發明的其他特徵與優點,在參照下面的較佳實施例 之詳細說明和隨文檢附的圖式後,將變得明顯,在圖式中: 圖1顯示,於3個以不同劑量的CHX來進行的病毒攻毒 試驗(virus challenge trial)中,在WSSV感染(縱軸)相對於假 感染(mock infection)(橫軸)的條件下,位在微陣列上的532 10個WSSV開放閱讀架構(〇RFs)的被正規化的Cy3螢先強度 (normalized Cy3 florescence)(亦即表現位準)的散佈圖,其 中 A組:12·5 mg/kg CHX處理;B 組:62·5 mg/kg CHX處理; 以及C組:250 mg/kg CHX處理;(iv) - a nucieic acid analogue of the nucleotide sequence of (1) having at least about 6% sequence identity to the nucleotide sequence of (1) and capable of driving an operably linked ( The expression of the target gene operatively connected to the nucleic acid analog; (v) a nucleic acid analog of the 5'-truncated fragment of (ii) having at least about a 5'-truncated fragment of (1)) 60% sequence identity and can drive the expression of a target gene operably linked to the nucleic acid analog; (vi) - a variant of the nucleotide sequence of (1), which contains at least one conserved species Sexual substitution (conservative subs_ti〇n), and can drive the expression of a target gene operably linked to the variant; and (VII) - a variant of the 5'-truncated fragment of (ii), Containing at least one constant substitution, and can drive the expression of a target gene operably linked to the variant. In the above-mentioned WSSV very early promoter, the nodal region can trigger the expression of a heterologous t-base in the non-small 彳 main cell, and thus can be used to construct 18 1296285 to construct various recombinant expression vectors for use. In the transformation - a wide range of primary cells. Thus, according to a second aspect, the vectors are constructed to contain *, and the wssv very early promoter regulatory region is operably linked to the target gene. According to a third aspect, the present invention provides a recombinant host cell which is produced by transforming a host cell with the above recombinant expression vector. 10 15 It is contemplated that the practice of the invention is not limited by the use of particular host cells. In fact, the invention can be applied to a wide variety of prokaryotic and eukaryotic host cells 'including bacterial cells, yeast cells, fungal cells, plant cells, insect cells, mammalian cells, etc., and can be used to produce Useful ribozymes and RNA transcripts, as well as different types of proteins, including: white shellfish present in the cytoplasm (4) 〇plasm) or pedpiasmic space, proteins or cells present on the cell membrane (ceu membrane) Proteins, as well as enzymes for use in the health, agriculture, food industry, brother industry, aquaculture and animal husbandry, especially pharmaceutical proteins and peptides such as interferons, human and animal hormones, immune antigens And antibodies. According to a fourth aspect, the present invention provides a primer set for the selection of a 4-week region of a WSSV very early 20 promoter, comprising a forward primer and a reverse primer, the forward primer being substantially One selected from the group consisting of sequence identification number 15 (i.e., the primer 126-lk-F shown in Table 2 described in the examples) and the sequence identification number: 17 (i.e., as described in the examples). The primer sequence i26-2k-F in Table 2 is composed of the nucleotide sequence of the nucleotide sequence 19 1296285, * the reverse primer is basically the phase identification number: 16 (also shown in The nucleotide sequence of the scorpion 126_R) in Table 2 described in the examples was constructed. BRIEF DESCRIPTION OF THE DRAWINGS Other features and advantages of the present invention will become apparent from the following detailed description of the preferred embodiments and the accompanying drawings, in which: FIG. In a virus challenge trial with different doses of CHX, 532 on the microarray under conditions of WSSV infection (vertical axis) versus mock infection (horizontal axis) A scatter plot of normalized Cy3 florescence (ie, performance level) of 10 WSSV open reading architectures (〇RFs), group A: 12·5 mg/kg CHX treatment; group B : 62·5 mg/kg CHX treatment; and Group C: 250 mg/kg CHX treatment;
圖2顯示3個WSSV IE基因候選物的ORFs (ORF126、 15 ORF242、ORF418)以及WSSV DNA聚合酶基因(如叩⑹(正 對照組)的瓊脂糖凝膠電泳(agarose gel electrophoresis) RT-PCR結果,其中Μ : 100 bp DNA階梯(Lambda Biotech Inc·,台灣);徑1 : 250 mg/kg CHX-預處理組的RT-PCR產 物;徑2 :載劑-預處理組(只有20%乙醇)的RT-PCR產物; 20 徑3 : 250 mg/kg CHX-預處理組的PCR產物;以及徑4 :從 WSSV基因組DNA被擴增出的PCR產物[擴增產物(amplicon) 大小參考品]; 圖3顯示在被所出示的質體轉染歷時72 h之後的Sf9昆 蟲細胞内的WSSV IE基因候選物的啟動子活性,其中該等 20 1296285 細胞在亮視野(BF組)與暗視野(EGFP組,用以觀察綠色螢光 的存在/不存在)下被檢視;比例尺=1〇〇 μιη ; 圖4顯示來自於圖3的相同經轉染的sf9昆蟲細胞的經 SDS-PAGE分開的細胞溶胞產物(SDS_pAGE separated cell 5 lysates)的西方墨點分析結果(Western blotting results),其中 該細胞溶胞產物的經墨點分析的總蛋白質(bl〇tted t〇tal proteins)是使用抗-EGFP或者抗-沒-肌動蛋白(對照組)抗體 來作探測,並且藉由一種ECL化學冷光系統(ECL chemiluminescence system)來作顯像; 10 圖5顯示WSSV化7轉錄本的5,和3,端的圖譜,其中被用 於5’ RACE和 3’ RACE的引子(126SP1、126SP2、126SP3和 128SP1)被劃底線,位在介於轉譯起始點(transiati〇I1 start) 前方的-92和-43 nt之間的陰影區域顯示可能的基本啟動子 要素(如NNPP程式所預測的);彎曲的箭頭表示轉錄起始位 15 址(transcriptional start sites),該位址是藉由定序7個隨機選 出的5’ RACE選殖株而被標示出;TATA和聚腺苷酸化訊號 (polyadenylation signal)(AATAAA)被分別地加框以及粗體 字化,以及聚(A)加入位址[p〇ly(A) addition site]是以一箭頭 來作標示; 20 圖6顯示WSSV DNA聚合酶、RIU、RR2以及IE1基因的 5’-未轉譯的區域(5’ UTR),其中起始開始位址扣⑽“也⑽ start)均位在TATA盒(TATA box)下游的〜26 nt處;該等 TATA盒被陰影標示,以及措由5 ’ RACE而被鑑定出的轉錄 起始位址是以彎曲的箭頭來作標示; 21 1296285 圖7顯示藉由RT-PCR而作的WS S V暫時轉錄分析的 結果,其中使用ki-特異性引子126F/126SP1 (Α組)、如叩Α 特異性引子(B組)與(C) vp2S-特異性引子(C組),而蝦冷-肌 動蛋白-特異性引子(D組)與基因間的(intergenic)引子 5 Ι(^Ρ2/Κ>Ϊ13(Ε組)被分別地用作為内部對照組;徑]v[是一 100 bp DNA階梯(Lambda Biotech Inc·,Taiwan),以及被標 示在其他徑上方的數字代表以感染後的小時數(hours p0St infection,hpi)來表示的轉染時間;以及 圖8顯示位在2 kbp WSSV化7啟動子/增強子區域内的 10 被預測的調節要素(regulatory motif)的DNA序列結構與位 置。 【實施方式3 較佳實施例之詳細說明 除非另外有所定義,本文中所使用的所有技術性與科 15 學術語具有熟悉本發明所屬技藝的人士所共同瞭解的意 義。為表清楚,下面的界定被使用於本文中。 本文中所用的“啟動子序列(promoter sequence)”此術 語是指一DNA序列,它通常是位在一DNA聚合體内所存在 的一個基因的上游處,而且它提供一用於起始該基因的轉 20 錄以生成1111^^^的位址。適用於本發明的實施的啟動子序 列可以是衍生自病毒(viruses)、嗟菌體(bacteriophages)、原 核細胞或真核細胞,而且可為一組成性啟動子(constitutive promoter)或是一誘導性啟動子(in(jucible promoter)。 當一個啟動子不是直接緊鄰於(亦即,共價地連接至) 22 1296285 ^系在匕所衍生而出的生物體的天然發生的基因組内所 鄰接的編碼序列時,該啟動子是經分離的。所謂“經分離 的,它是指一種經分離的物質已經與它在其他情況[例 如’活體内(Z>2 V/V0)]下會締合的其他組份(諸如生物組份) 、貝也刀開或疋被純化出,精此,该經分離的物質本身可 以被操作或處理。“經分離的”此術語因此包括:藉由標準 純化方法而被純化出的物質、藉由重組DNA技術而於一宿 主内所製得的物質以及化學合成的物質。因此,可以預期 到,依據本發明的經分離的WSSV極早期啟動子-調節區域 10可以藉由從天然來源來作分離、化學合成以及重組DNA技 術而被獲得。 15 20 轉錄與轉譯的控制序列是DNA調節序列,諸如啟動 子、增強子(enhancer)、聚腺苔酸化訊號(p〇lyadenylati〇n signal)、終止子(terminat〇r)以及類似物,它們提供一編碼序 列在一宿主細胞内的表現。一“順式要素,,是一種核苔酸序 列匕會與可以增量調控(uPre§ula⑹或減量調控(upregulate) 特定基因位點(gene 1〇cus)的表現的蛋白質互相作用。 某些DNA序列,它們通常位在_DNA聚合體内的一個 基因之則,ϋΕ且提供一用於起始該基因的轉錄而成為 mRNA的位址,被稱為“啟動子,,序列。其他的麵或臟 序列^疋但’又有必要位在一結構基因的“上游,,處)會結 合那些決定轉錄和/或轉譯起始的頻度或速率的蛋白質。這 些其他的序列,包拉^ 依弱化子(attenuator)、增強子、操縱基 因(operator)與類似物 被矛冉為调控子(regultor)”序列。因 23 1296285Figure 2 shows the results of agarose gel electrophoresis RT-PCR of ORFs (ORF126, 15 ORF242, ORF418) of three WSSV IE gene candidates and WSSV DNA polymerase gene (such as 叩(6) (positive control group). , where Μ : 100 bp DNA ladder (Lambda Biotech Inc., Taiwan); diameter 1: 250 mg/kg RT-PCR product of CHX-pretreatment group; diameter 2: vehicle-pretreatment group (only 20% ethanol) RT-PCR product; 20 PATH 3: 250 mg/kg PCR product of the CHX-pretreatment group; and PATH 4: PCR product amplified from WSSV genomic DNA [amplicon size reference]; Figure 3 shows the promoter activity of WSSV IE gene candidates in Sf9 insect cells after 72 h of plastid transfection as shown, wherein these 20 1296285 cells were in bright field (BF group) and dark field (EGFP). Groups, to observe the presence/absence of green fluorescence, were examined; scale = 1 〇〇 μιη; Figure 4 shows SDS-PAGE-separated cell lysis from the same transfected sf9 insect cells of Figure 3. Western blotting results of SDS_pAGE separated cell 5 lysates (Western blotting re Sults), wherein the total protein (bl〇tted t〇tal proteins) of the cell lysate is detected using anti-EGFP or anti-no-actin (control) antibody, and Imaging by an ECL chemiluminescence system; 10 Figure 5 shows the 5, and 3, end of the WSSV 7 transcript, which was used for 5' RACE and 3' RACE primers (126SP1) 126SP2, 126SP3, and 128SP1) are underlined, and the shaded area between -92 and -43 nt in front of the translation start point (transiati〇I1 start) shows possible basic promoter elements (as predicted by the NNPP program) The curved arrow indicates the transcriptional start sites, which are indicated by sequencing 7 randomly selected 5' RACE strains; TATA and polyadenylation signals The polyadenylation signal (AATAAA) is framed and bolded separately, and the poly (A) addition site [p〇ly(A) addition site] is indicated by an arrow; 20 Figure 6 shows WSSV DNA 5'-untranslated of polymerase, RIU, RR2 and IE1 genes Region (5' UTR), where the starting start address deduction (10) "also (10) start) is located at ~26 nt downstream of the TATA box; these TATA boxes are shaded and the 5 ' RACE The identified transcription initiation site is indicated by a curved arrow; 21 1296285 Figure 7 shows the results of a transient transcriptional analysis of WS SV by RT-PCR using ki-specific primer 126F/126SP1 (Α group), such as 特异性 specific primer (group B) and (C) vp2S-specific primer (group C), while shrimp cold-actin-specific primer (group D) and intergenic (intergenic) The primer 5 Ι(^Ρ2/Κ>Ϊ13 (Ε group) was used as the internal control group separately; the diameter]v [is a 100 bp DNA ladder (Lambda Biotech Inc., Taiwan), and was marked above other diameters) The number represents the transfection time expressed as hours p0St infection (hpi); and Figure 8 shows the 10 predicted regulatory elements in the 2 kbp WSSV 7 promoter/enhancer region (regulatory The motif and location of the DNA sequence. [Embodiment 3] DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art. For clarity, the following definitions are used herein. As used herein, the term "promoter sequence" refers to a DNA sequence which is usually located upstream of a gene present in a DNA polymer and which provides a gene for initiating the gene. Turn 20 to generate the address of 1111^^^. Promoter sequences suitable for use in the practice of the invention may be derived from viruses, bacteriophages, prokaryotic cells or eukaryotic cells, and may be a constitutive promoter or an inducible Promoter (in(jucible promoter). When a promoter is not directly adjacent to (ie, covalently linked to) 22 1296285 ^ is a contiguous coding within the naturally occurring genome of an organism derived from 匕In the case of sequence, the promoter is isolated. By "separated, it refers to an isolated substance that has been associated with it under other conditions [eg, 'in vivo (Z> 2 V/V0)). Other components (such as biological components), scallops or mites are purified, and the isolated material itself can be manipulated or processed. The term "isolated" thus includes: by standard purification methods And the purified material, the substance produced by a recombinant DNA technique in a host, and the chemically synthesized substance. Therefore, it is expected that the isolated WSSV very early promoter-adjusted according to the present invention Domain 10 can be obtained by isolation, chemical synthesis, and recombinant DNA techniques from natural sources. 15 20 Regulatory sequences for transcription and translation are DNA regulatory sequences, such as promoters, enhancers, and poly-tartification signals. (p〇lyadenylati〇n signal), terminator (r) and analogs, which provide a coding sequence for expression in a host cell. A "cis-element, a chlorophyll sequence" Incremental regulation (uPre§ula(6) or downregulation of protein expression in specific gene loci (gene 1〇cus). Certain DNA sequences, which are usually located in a gene in a _DNA polymer, And providing a site for initiating transcription of the gene to become mRNA, referred to as "promoter, sequence. Other face or visceral sequences" but "needs to be located "upstream" of a structural gene , , in combination with those proteins that determine the frequency or rate at which transcription and/or translation initiation begins. These other sequences, including attenuator, enhancer, and operator (operato) r) and analogues are spears as regulators. Sequences 23 1296285
此,會操縱以決定_基因的轉錄與最後的表現是否要發生 的序列被集合土也稱作為“啟動子/調控子,,DNA序列。X -個DNA‘‘編碼序列,,是—雙股疆序列,當被置於適 當的調節序列的控制下時,它於活體内被轉錄成RNA,而 5该RNA被轉澤成-多肽。該編碼序列的邊界是以一個位在 5’(胺基)端的起始密碼子與一個位在3,(絲)端的終止密碼 子來決定。一個編碼序列可包括,但不限於:原核生物的 序列、來自會感染原核生物或真核生物的病毒的基因組的 序列、來自真核細的cDNA、來自真核生物(例如, 10哺乳動物)的DNA的基因組DNA序列,以及甚至是合成的 DNA序列。——個聚腺苷酸化訊號與轉錄終止序列通常是位 在該編碼序列的下游處。一個“cDna”被定義為複本-DnA (copy DNA)或互補-DNA (complementary DNA),並且是一 來自一個mRNA轉錄本的反轉錄反應(reverse transcripti〇n 15 reaction)的產物。 一個“訊息序列”亦可被包含在該編碼序列之内,並且 編碼一個位在該多肽的N-端處的訊息胜肽,該訊息胜肽與 宿主細胞溝通並且指引該多肽至適當的細胞位置處。訊息 序列可被發現與原核生物和真核生物所天然擁有的各種不 20 同的蛋白質相締合。 本文中所使用的術語“核酸”以及“核酸序列,,是指一呈 單股或雙股形式的去氧核糖核苷酸或核糖核苷酸序列,該 序列包含有天然存在的以及已知的核苷酸或是人造化學仿 效物(aritificial chemical mimics)。本文中所用的“核酸”此術1 24 1296285 語可與術語“基因,,、“cDNA,,、“mRNA,,、“募核苷酸,,和‘‘聚 核苷酸”交換使用。 除非另有指明,一核酸序列除了於本文中所揭示的特 疋序列外’亦涵蓋其互補序列(complementary sequences), 5 以及它們的守恆性類似物(conservative analogs)、相關的自 然存在的結構變異體和/或合成的非自然存在的類似物。例 如具有簡併性密碼子取代(degenerative codon substitutions) 的同源性序列(homologous sequences)。特別地,組成性取 代可以藉由,例如,位於本文中所揭露的特定序列的一個 10 核甘酸殘基處的一個核苷酸殘基取代而被產生,而不影響 該序列的啟動子活性。 “重組DNA技術”意指用於聯合兩種異源性DNA分子的 技術,通常是來自於不同生物體的DNAs的活體外接合的一 個結果。重組型DNA分子通常是藉由遺傳工程的實驗而被 15 產生。同義的術語包括“基因剪接(gene splicing)”、“分子選 殖(molecular cloning)”和“遺傳工程(genetic engineering)”。 這些操作的產物形成一種“重組體”或“重組型分子”。 用來操作核酸的技術,諸如那些用於產生序列中的突 變(mutation)、次選殖(subcloning)、標示(labelling)、探針檢 20 測(probing)、定序(sequencing)、雜交(hybridization)等等, 在科學刊物和專利文獻中皆有詳細說明。參見,例如:Thus, the sequence that will be manipulated to determine whether the transcription and final expression of the gene are to be generated is also referred to as "promoter/regulator, DNA sequence. X-DNA'' coding sequence, is - double strand The sequence, when placed under the control of an appropriate regulatory sequence, is transcribed into RNA in vivo, and 5 the RNA is transduced into a polypeptide. The boundary of the coding sequence is at one position at 5' (amine) The start codon at the basal end is determined by a stop codon at position 3, (silk). A coding sequence can include, but is not limited to, a sequence of a prokaryote, a virus from a prokaryotic or eukaryotic organism. The sequence of the genome, the cDNA from eukaryotic cDNA, the genomic DNA sequence of DNA from eukaryotes (eg, 10 mammals), and even the synthetic DNA sequence. - A polyadenylation signal and transcription termination sequence are usually Is located downstream of the coding sequence. A "cDna" is defined as a copy-DnA (copy DNA) or a complementary-DNA (complementary DNA) and is a reverse transcription reaction from an mRNA transcript (reverse transcripti a product of 〇n 15 reaction. A "message sequence" can also be included within the coding sequence and encode a message peptide at the N-terminus of the polypeptide that communicates with the host cell and Directing the polypeptide to the appropriate cellular location. The message sequence can be found to associate with various proteins that are naturally possessed by prokaryotes and eukaryotes. The terms "nucleic acid" and "nucleic acid sequence," , refers to a single or double-stranded form of deoxyribonucleotide or ribonucleotide sequence containing naturally occurring and known nucleotides or aritificial chemical mimics . As used herein, "nucleic acid" is used interchangeably with the terms "gene,", "cDNA,," "mRNA,", "nucleotide, and 'polynucleotide" unless It is also indicated that a nucleic acid sequence encompasses complementary sequences, in addition to the specific sequences disclosed herein, 5 and their conservative analogs, associated naturally occurring structural variants. And/or synthetic non-naturally occurring analogs, such as homologous sequences with degenerative codon substitutions. In particular, constitutive substitutions can be made, for example, by A nucleotide residue at a 10-nucleotide residue of a particular sequence disclosed is substituted without affecting the promoter activity of the sequence. "Recombinant DNA technology" means for combining two heterogeneities The technique of DNA molecules is usually a result of in vitro ligation of DNAs from different organisms. Recombinant DNA molecules are usually experiments by genetic engineering. Generics are produced by 15. Synonymous terms include "gene splicing," "molecular cloning," and "genetic engineering." The products of these operations form a "recombinant" or "recombinant" Molecules. Techniques for manipulating nucleic acids, such as those used to generate mutations in a sequence, subcloning, labelling, probing, sequencing, Hybridization, etc., are described in detail in scientific journals and patent documents. See, for example:
Sambrook J, Russell DW (2001) Molecular Cloning: a Laboratory Manual, 3rd ed. Cold Spring Harbor Laboratory Press, New York; Current Protocols in Molecular Biology, 25 1296285Sambrook J, Russell DW (2001) Molecular Cloning: a Laboratory Manual, 3rd ed. Cold Spring Harbor Laboratory Press, New York; Current Protocols in Molecular Biology, 25 1296285
Ausubel ed., John Wiley & Sons, Inc., New York (1997); Laboratory Techniques in Biochemistry and Molecular Biology: Hybridization With Nucleic Acid Probes, Part I, Theory and Nucleic Acid Preparation, Tijssen ed., Elsevier, 5 Ν·Υ· (1993)。 兩個聚核苷酸的序列相同性(sequence identity)可以藉 由熟悉此項技藝的人士已知的數種不同的方法而被決定, 包括,但不限於,Altschul等人的BLAST程式(/. Mo/.价说, 215, 403-410, 1990) 〇 10 為了界定本發明,一個啟動子區域被界定為在它的3, 端處以轉錄起始位址作為邊界,並且往上游(非轉錄股的5, 方向)延伸而包含要起始處在高於背景值的可偵測位準下 的轉錄所需要的最小數目的核苷酸。此外,一啟動子區域 的序列可以往上游(非轉錄股的5,方向)延伸俾而包含所有 15 會定性地或定量地影響該啟動子區域的操作和/或效率的 核苷酸。在該啟動子區域序列之内會發現到有一個轉錄起 始位址’還有負責RNA聚合酶的結合的蛋白質結合領域。 真核生物的啟動子通常,但非總是,含有“TATA”盒與“CAT,, 盒0 本文中所用的術語“被可操作地連結至(〇peratively connected)”是指一個第一序列被配置在充分接近於一個第 二序列,而使得該第一序列可影響該第二序列或處在該第 二序列控制之下的區域。例如,一啟動子序列可被可操作 地連接至一基因序列,且通常是在該基因序列的5,端位 26 1296285 置而使得.亥基因序列的表現是在該啟動子序列的控制之 下此外,一调節序列可被可操作地連接至一啟動子序列, 俾以增強該啟動子序列啟動轉錄的能力。在這種情況下, 該調節序列通常是位在該啟動子序列的5,端處。 5 本文中所用的術語“表現載體,,是指任何一種重組型表 現系統,匕可於活體外(/n 或活體内(ίη νζ·νο),在任何 種佰主細胞内構成地(c〇nstitutively)或誘導地(inducibly) 表現一被選定的核酸序列。該表現載體可為一呈線性或環 狀形式的表現系統,並且涵蓋維持游離基因(episomal)形式 1〇或是被整合至宿主細胞的基因組内的表現系統。該表現系 統可具有或不具有自我複製的能力,並且它在一宿主細胞 内可能只驅動暫時性表現(transient expression)。 根據本發明’當術語“轉形(transformati〇n)’’是指將一外 源性核酸分子引入至一選定的宿主細胞内時,該術語可與 I5術语‘轉染(transfection)”互換地使用。依據本技藝中已知的 技術,一核酸分子(例如,一重組型DNA建構物或一重組型 載體)可藉由各種不同的技術而被引入至一選定的宿主細 胞内,諸如磷酸鈣或氯化鈣媒介的轉染作用(calcium phosphate- or calcium chloride-mediated transfection) > 電穿 20 孔法(electroporation)、微注射法(microinjection)、粒子揞擊 法(particle bombardment)、脂質體媒介的轉染作用 (liposome-mediated transfection)、使用嗟菌體的轉染作用、 利用反轉錄病毒(retrovirus)或其他病毒[諸如牛痘病毒 (vaccinia virus)或昆蟲細胞的桿狀病毒(baculovirus)]的轉導 27 1296285 作用(transduction)、原生質體融合法(protoplast fusion)、農 桿菌媒介的轉形法(Agrafeacia/wm-mediated transformation) 或其他方法。 本文中所用的術語“細胞’’、“宿主細胞’’、“轉形宿主細 5 胞(transformed host cell)”與“重組型宿主細胞(recombinant host cell)”可被互換地使用,而且不僅指特定的個體細胞 (individual cells),還包括繼代培養的子代(sub-cultured offsprings)或其可能的子代(potential offsprings)。在後續世 代中所形成的繼代培養的子代可能因為突變作用或環境影 10 響而發生特定的遺傳修飾(genetic modification),因此,該 繼代培養的子代可能事實上不完全相同於衍生出該繼代培 養的子代的母細胞。然而,繼代培養的細胞仍然落在本文 中所用的術語的涵蓋範疇内。 本文中所用的術語“多肽”、“胜肽”和“蛋白質”可被互換 15 地使用,並1是指一種由胺基酸殘基所構成的聚合物,其 中一或多個胺基酸殘基是天然存在的胺基酸或人造化學仿 效物。 在申請人較早的研究中,一種WSSV的病毒分離株,亦 即草蝦1994 台灣分離株(WSSV 20 T-1),它是分離自草蝦(Pen似w m⑽,已根據布達佩 斯條約(Budapest Treaty)而於1996年1月11日被寄存於中國 典型培養物保藏中心(the China Center for Type Culture Collection (CCTCC),武漢大學,珞珈山,武漢,湖北, 430072,中華人民共和國),並且被給予寄存編號 28 1296285 CCTCC-V96001 (參見授予郭光雄等人的仍5,824,53^us 6,190,862 以及 L.-L· C7z⑼ 从(2002),3〇人 D6-W7)。這個台灣分離株的完整基因組隨後被定序,並且 經由直接提送而以登錄編號AF440570被登錄於NCBI資料 5 庫中。 就申請人所知,迄今沒有任何一篇報導有鑑定出WSSV 極早期(IE)基因。於本發明中,申請人使用放射菌酮(CHX) 作為一種抑制劑來阻遏WSSV-感染的蝦體内的病毒從頭蛋 齡白質合成,繼而藉由根據使用衍生自WSSVT-1的532 0RFS 10的特異性引子(參見描述於下面的實施例中的表1}而得的 WSSV PCR產物所設計的WSSv DNA (0RF/基因)微陣列來 檢查病毒極早期基因的RNA轉錄本。可能為WSSV極早期基 因候選物的3種〇RFs,亦即ORF126、ORF242和ORF418, 被成功地4監定出。一個有關3種至今為止有被報導的WSSV 15分離株的基因組序列比對顯示:在這3個已知的WSSV分離 株中’這3個〇RFs沒有一個有發生過刪除。ORF126、〇RF242 ® 與〇1^418因此被分別地命名為WSSV Μ (極早期基因 、ie2與ie3 〇 個短暫報導基因分析(transient reporter assay)隨後被 20執行,以探究這3種WSSVIE基因候選物的啟動子區域於一 非天然的宿主細胞(例如Sf9昆蟲細胞)内觸發一個異源性基 因[例如’增強的綠色螢光蛋白質(EGFP)基因]的表現的可 此性’該基因於該分析中亦當作一個報導基因。被用於構 ‘短暫表現載體(transient expression vectors)的引子被列在 29 1296285 描述於貫施例中的表2。出人意料地,依據本發明而被選殖 出的WSSV W的1 kbp和2kbp啟動子區域在WSSV的非天然 宿主細胞内是有功能的,這暗示該WSSV id的啟動子區域 在供應用於構築用來轉形一廣泛範圍的宿主細胞的各種不 5同的重組型表現載體上具有極大的潛能。 WSSV化/被進一步進行使用描述於實施例中的表3内 所列的引子的5,/3,RACE分析。所獲得的結果顯示:相對於 ATG轉譯起點的-52 nt G代表WSSV化7的主要轉錄起始 點。另外,一個推定的TATA盒(TATAA)被發現位於轉錄起 10始位址的上游(-26 nt)(亦即位在相對於ATG轉譯起點的_82 nt至-78 nt處)。該tata要素(TATA motif)與轉錄起始子一 起被認為是RNA聚合酶II啟動子的基本要素。WSSv w推 定的轉錄起始位址的上游序列的NNPP [有關於啟動子預測 的中樞網路(Neural Network for promoter prediction)]分析 15鑑定出一個高可能性的被預測的基本啟動子區域是位在推 疋的轉澤起始密碼子前方的-92 nt和-43 nt之間。此外,由 啟動子活性分析所得到的實驗結果暗示wssv 的轉錄不 受限於它的天然宿主的RNA聚合酶II。 另外,依據核苷酸序列分析,該WSSVid的5, UTR(未 20轉譯的區域)被發現包含有數個序列是符合於GATA要素 (A/T)GATA(G/A)的共有序列(consensus seqUences)。這可能 是重要的,因為該G A T A要素被確認是轉錄因子的一個結合 位址,例如在桿狀病毒0pMNPV IE基因,卯64,的啟動子 內(Ρ·Η· Kogan and G.W. Blissard (1994),j· virol·,68 30 1296285 S73-S22)。亦存在數個其他可能的調節要素,包含:2個直 接重複序歹U (CACACACA與CTCTCTCTCT)、2#1短序歹ij白勺 重複(TTTCTGG與CCAGAAA)、桿狀病毒早期基因啟動子 要素(上游調節要素)(CGTGC)(/?.Z>. and B.c. 5 jBcmmTig (2003J,/· S岑(Pi 7人 7S27-7842)、桿狀 病毒晚期啟動子起始子(TTAAG)(L.A. Gwar/⑽and M.叱Ausubel ed., John Wiley & Sons, Inc., New York (1997); Laboratory Techniques in Biochemistry and Molecular Biology: Hybridization With Nucleic Acid Probes, Part I, Theory and Nucleic Acid Preparation, Tijssen ed., Elsevier, 5 Ν ·Υ· (1993). The sequence identity of the two polynucleotides can be determined by a number of different methods known to those skilled in the art, including, but not limited to, the BLAST program of Altschul et al. Mo/. Price, 215, 403-410, 1990) 〇10 To define the present invention, a promoter region is defined as having a transcription start site at its 3' end, and upstream (non-transcribed strand) The 5, direction) extends to contain the minimum number of nucleotides required to initiate transcription at a detectable level above the background value. In addition, a sequence of promoter regions can be extended upstream (in the 5, direction of the non-transcribed strand) to contain all of the nucleotides that will affect the operation and/or efficiency of the promoter region qualitatively or quantitatively. Within the sequence of promoter regions, a transcription initiation site' and a domain of protein binding responsible for the binding of RNA polymerase will be found. The promoter of eukaryotes usually, but not always, contains a "TATA" box and "CAT," box 0. The term "operably connected" is used herein to mean that a first sequence is Arranged in close proximity to a second sequence such that the first sequence can affect the second sequence or a region under the control of the second sequence. For example, a promoter sequence can be operably linked to a gene a sequence, and usually at the 5, terminus 26 1296285 of the gene sequence such that the expression of the gene sequence is under the control of the promoter sequence. Additionally, a regulatory sequence can be operably linked to a promoter. a subsequence, 俾 to enhance the ability of the promoter sequence to initiate transcription. In this case, the regulatory sequence is typically located at the 5' end of the promoter sequence. 5 The term "expression vector, as used herein, is Refers to any recombinant expression system that can be selected in vitro (/n or in vivo (ίη νζ·νο), in any species of host cell, c〇nstitutively or inducibly Nucleic acid sequence. The expression vector can be a display system in a linear or circular form and encompasses a system of expression that maintains the episomal form 1 〇 or is integrated into the genome of the host cell. Or does not have the ability to self-replicate, and it may only drive transient expression in a host cell. According to the invention 'when the term 'transformi〇n'' refers to an exogenous nucleic acid When a molecule is introduced into a selected host cell, the term can be used interchangeably with the I5 term 'transfection.' A nucleic acid molecule (eg, a recombinant DNA construct, according to techniques known in the art) Or a recombinant vector) can be introduced into a selected host cell by a variety of different techniques, such as calcium phosphate- or calcium chloride-mediated transfection > Transfection by 20-well electroporation, microinjection, particle bombardment, liposome mediation Transduction with (liposome-mediated transfection), transfection with sputum, retrovirus or other viruses [such as baccinvirus of vaccinia virus or insect cells] 1296285 Transduction, protoplast fusion, Agrafeacia/wm-mediated transformation or other methods. The terms "cell", "host cell", "transformed host cell" and "recombinant host cell" as used herein are used interchangeably and refer not only to Specific individual cells also include sub-cultured offsprings or their potential offsprings. Subcultured progeny formed in subsequent generations may undergo specific genetic modification due to mutation or environmental impact, and therefore, the subcultured progeny may not actually be identical to the derivative. The mother cells of the subcultured progeny. However, subcultured cells still fall within the scope of the terminology used herein. The terms "polypeptide", "peptide" and "protein" as used herein may be used interchangeably, and 1 refers to a polymer composed of amino acid residues in which one or more amino acid residues are present. The base is a naturally occurring amino acid or an artificial chemical analog. In an earlier study by the applicant, a WSSV virus isolate, also known as the grass shrimp 1994 Taiwan isolate (WSSV 20 T-1), was isolated from grass shrimp (Pen like w m (10), according to the Budapest Treaty (Budapest) Treaty) was deposited at the China Center for Type Culture Collection (CCTCC), Wuhan University, Lushan, Wuhan, Hubei, 430072, People's Republic of China on January 11, 1996, and It is given the registration number 28 1296285 CCTCC-V96001 (see also granting Guo Guangxiong et al. still 5,824, 53^us 6,190,862 and L.-L·C7z(9) from (2002), 3〇D6-W7). This Taiwan isolate The complete genome was then sequenced and logged into the NCBI Data Library 5 via direct delivery under accession number AF440570. To the best of the Applicant's knowledge, none of the reports have identified the WSSV Very Early (IE) gene. In the present invention, Applicants used oxycodone (CHX) as an inhibitor to repress the virus from WSSV-infected shrimps from the primordial white matter synthesis, and then by using 532 0 RFS 10 derived from WSSVT-1 according to use. The WSSv DNA (0RF/gene) microarray designed by the WSSV PCR product of the specific primer (see Table 1 in the following examples) was used to examine the RNA transcript of the very early viral gene. It may be very early for WSSV. The three 〇RFs of the gene candidate, namely ORF126, ORF242 and ORF418, were successfully monitored. A genomic sequence alignment of the three previously reported WSSV 15 isolates showed: None of the three 〇RFs in the known WSSV isolates have been deleted. ORF126, 〇RF242 ® and 〇1^418 were therefore named WSSV 分别 (very early genes, ie2 and ie3) were briefly reported. A transient reporter assay is then performed by 20 to explore that the promoter regions of the three WSSVIE gene candidates trigger a heterologous gene in a non-native host cell (eg, Sf9 insect cells) [eg, enhanced The expression of the green fluorescent protein (EGFP) gene] is also used as a reporter gene in this analysis. The primer used to construct the transient expression vectors was Table 2 is described in the Examples in Example 2. Surprisingly, the 1 kbp and 2 kbp promoter regions of WSSV W selected according to the present invention are functional in WSSV non-native host cells, suggesting The promoter region of the WSSV id has great potential for supplying a variety of recombinant expression vectors for constructing a wide range of host cells for transformation. WSSVization/further analysis was performed using the 5,/3, RACE analysis of the primers listed in Table 3 in the examples. The results obtained show that -52 nt G relative to the ATG translation start point represents the major transcriptional initiation point of WSSV7. In addition, a putative TATA box (TATAA) was found upstream (-26 nt) from the start of transcription (ie, at _82 nt to -78 nt relative to the start of the ATG translation). This tata motif, together with the transcriptional initiator, is considered to be an essential element of the RNA polymerase II promoter. The NNPP of the upstream sequence of the putative transcription start site of WSSv w [Neural Network for promoter prediction] analysis 15 identifies a high probability that the predicted basic promoter region is a bit Between -92 nt and -43 nt in front of the tweet start codon. Furthermore, the experimental results obtained by promoter activity analysis suggest that transcription of wssv is not restricted to its native host RNA polymerase II. In addition, according to the nucleotide sequence analysis, the WSSVid 5, UTR (region not translated) was found to contain several sequences that are consistent with the GATA element (A/T) GATA (G/A) consensus sequence (consensus seqUences) ). This may be important because the GATA element is identified as a binding site for the transcription factor, for example in the promoter of the baculovirus 0pMNPV IE gene, 卯64, (Ρ·Η·Kogan and GW Blissard (1994), j· virol·, 68 30 1296285 S73-S22). There are also several other possible regulatory factors, including: 2 direct repeats 歹U (CACACACA and CTCTCTCTCT), 2#1 short-order 歹ij repeats (TTTCTGG and CCAGAAA), baculovirus early gene promoter elements ( Upstream Regulatory Factors) (CGTGC) (/?.Z>. and Bc 5 jBcmmTig (2003J, /· S岑 (Pi 7 human 7S27-7842), baculovirus late promoter promoter (TTAAG) (LA Gwar/ (10) and M.叱
Smith (1990),Virology,179,1-8\ T.D. Morris and L.K·Smith (1990), Virology, 179, 1-8\ T.D. Morris and L.K·
Mi…r (7994),7祁,以7」53),以及一個可產生有如一 轉錄增強子的功能的迴文序列(palindromic seqnence)(C. Γ. 10 McMurray et al. (1991),Proc· Natl· Acad· Sci· USA·,88, 666-670·,C· Rasmussen et al. (1996),Virology,224, 235-245) 〇 除了上述以外,被選殖的3’ RACE產物的序列分析顯示 聚(A)被加入在一個位於AATAAA聚腺苷酸化訊號的下游 15 的17 nt位址處(參見圖5)。Mi...r (7994), 7祁, 7” 53), and a palindromic seqnence that produces a function as a transcriptional enhancer (C. Γ. 10 McMurray et al. (1991), Proc · Natl·Acad·Sci·USA·, 88, 666-670·, C. Rasmussen et al. (1996), Virology, 224, 235-245) In addition to the above, the sequence of the selected 3' RACE product Analysis showed that poly(A) was added at a 17 nt address downstream of 15 of the AATAAA polyadenylation signal (see Figure 5).
GenBank/EMBL、SWISSPROT和 PIR 資料庫的 BLAST 分析預測該WSSV id編碼區域含有Cys2/His2-型鋅指要素 (Cys2/His2-type zinc finger motif)。這個要素在DNA結合上 具有一角色,而它的存在暗示該WSSV 可能產生有如一 20 轉錄因子的功能。 WSSV W的被選殖出的2 kbp啟動子區域[它是藉由使 用引子126-2k-F (序列辨識編號:17)和引子126-R (序列辨 識編號:16)的PCR而被擴增出]的核苷酸序列被顯示於序列 辨識編號:29中。該WSSV 編碼區域的核苷酸序列以及 31 1296285 一為其所編碼的推定的胺基酸序列被分別地顯示於序列辨 識編號:30和序列辨識編號:31中。 根據以上所述,本發明提供一種經分離的Wssv極早期 啟動子-調節區域,它基本上是由一選自於下列群組中的核 5 苷酸序列所構成: ⑴一為序列辨識編號:29的核苷酸序列; (ii) 一為⑴的核苷酸序列的5、截短的片段(5,七uncated fragment) ’它具有由序列辨識編號:29的3,端算起 # 的至少92個核苷酸殘基; 10 (丨丨丨)一核酸序列,它是由使用一白點症病毒(WSSV)基 因組DNA作為模板以及一具有一順向引子與一反 向引子的引子組的聚合酶連鎖反應(P〇lymeraSe chain reaction)而被擴增出,該順向引子基本上是由 一選自於如序列辨識編號:15與序列辨識編號:π 15 所示的核笞酸序列當中的核苷酸序列所構成,而該 反向引子基本上是由一為序列辨識編號·· 16的核苷 • 酸序列所構成; (iv) —為⑴的核苔酸序列的核酸類似物(nucleic acid analogue),它與⑴的核苷酸序列具有至少大約60% 20 的序列相同性,並且可以驅動一被可操作地連結 (operatively connected)至該核酸類似物的標的基因 的表現; (v) —為(ii)的5’-截短的片段的核酸類似物,它與出)的 5’-截短的片段具有至少大約60%的序列相同性,並 32 I296285 且可以驅動一被可操作地連結至該核酸類似物的 標的基因的表現; (vi) —為⑴的核苷酸序列的變異體(variant),它含有至 少一個守恆性取代(conservative substitution),並且 可以驅動一可被操作地連結至該變異體的標的基 因的表現;以及 (vii) —為⑻的5’-截短的片段的變異體,它含有至少_ 個守恆性取代,並且可以驅動一被可操作地連結至 該變異體的標的基因的表現。 10 15 20 依據本發明,當該經分離的WSSV極早期啟動子-調節 區域基本上是由⑴的核苷酸序列的一個5,_截短的片段所構 成時’它較佳地具有由序列辨識編號·· 29的3,端算起的至 少160個核苷酸殘基。更佳地,該⑴的核苷酸序列的5,〜截短 的片段具有由序列辨識編號:29的3’端算起的至少25〇個桉 4酸殘基。更佳地,該_核㈣序列的5,截短的片段^ 有由,列辨識編號:29的3,端算起的至少5_核誓酸^ 基。取佳地,該⑴的核答酸序列的截短的片段具有二 列辨硪編號:29的3’端算起的至少1_個核^:酸殘基。 依據本發明,該經分離的極早期啟動 擴增反應而被;ΓΓ子和一反向引子的引子組的。cr 列辨識編號:恤序=向引子基本上是由—選自於如序 辨識職:17所示的核t 汁幻所構成,而該反向引子基本上是由_為序 33 1296285 列辨識編號:16的核苷酸序列所構成。在本發明的一個較 佳具體例中,該DNA模板是萃取自台灣分離株WSSVT-1, 該分離株的樣品以寄存編號CCTCC-V96001被寄存於中國 典型培養物保藏中心。 5 依據本發明,該經分離的WSSV極早期啟動子^周節區 域也可以包括序列辨識編號:29的核苷酸序列的守恆性變 異體(conservative variants)以及合成的類似物(synthetic analogues)[諸如序列的刪除(deieti〇n)、插入(inserti〇n)、反 置(inverison)、取代(substitution)或加入(addition)],但有條 10件是該等變異體和類似物可以同樣地觸發位在它的下游處 並且被可操作地連結的序列的轉錄。 在各種不同的具體例中,該等變異體與類似物可與被 使用前文中的該術語是實質同源的,或是當使用前文中所 載述的演算法來測定時,有大於60%、7〇%至1〇〇%、至少 15 80%、至少9〇%或至少95%的相同性。 依據本發明,該經分離的WSSV極早期啟動子_調節區 域可以被攜帶於一個表現匣内。如本文中所用的,術語‘‘表 見匣疋‘一個被合成地或重組地產生的核酸建構物,它攜 系列的核酸要素以允許一個特定的核酸在一標的細胞 〇内的轉錄與轉譯。各種不同的策略可以供應用於組合或接 合DNA的片段,並且依照該等£^八片段的終端的本質而 定,一合適的策略對於熟悉此項技藝人士而言會是立即就 明白的。 上述的WSSV極早期啟動子_調節區域能夠驅動一異源 34 1296285 (translation termination site)、一 插入選殖位置(insertion cloning location)、一增強子序列(enhancer sequence)、一個 聚腺苷酸化位址(polyadenylation site)、一調節序列等等。 另外,本發明的載體可以包含有一有關於一或多個限制内 5 切酶辨識位址(restriction endonuclease recognition sites)的 核苷酸序列。這些序列是熟習此項技術人士所熟知的。 適用於本發明的標記基因包括,例如,用於真核細胞 培養物的二氫葉酸還原酶基因以及G418或新黴素 (neomycin)抗性基因,用於昆蟲細胞培養物的Zeocin抗性基 10 因,以及用於大腸桿菌與其他細菌培養物的胺苄青黴素 (ampicilin)、鏈黴素(streptomycine)、四環素(tetracycline) 或康那黴素(kanamycine)抗性基因。 在本發明的一個較佳具體例中,該重組型表現載體進 一步包含有一個第二標的基因坐落在另一個啟動子序列的 15 下游且被可操作地連結至該另一個啟動子序列,該另一個 啟動子序列可以是或者不是一個本文中所揭露的wssv極 早期啟動子-調節區域。 依據本發明,該第一和第二標的基因獨立地編碼一個 選自於下列所構成的群組中的基因產物:酵素、治療性多 20 肽、抗原決定位和抗體。 在本發明的一個較佳具體例中,該重組型表現載體是 pIZME/WSSV126-2k/V5-EGFP-His。 在本發明的另一個較佳具體例中,該重組型表現載體 是pIZAIE/WSSV126-lk/V5-EGFP-His。 36 1296285 、 、的重"且型表現載體可以被用來轉形或轉染一被欲 ,勺侣主田胞。因此,本發明提供重組型宿主細胞,它們 、t的重組型表現載體來轉形宿主細胞而被產生的。 可以預期到本發明的實施並不受限於使用特定的宿主 5細胞。事貫上,本發明可以被應用至各式各樣的原核與真 核招主細胞’包括:細菌細胞、酵母菌細胞、真菌細胞、 植物細胞、昆蟲細胞、哺乳動物細胞等等,並且可以被用 來生產有用的核酶和RNA轉錄物,以及不同種類的蛋白 貝匕括存在於細胞質或近膜間隙(periplasmic space)内 10的蛋白、存在於細胞膜上的蛋白質或細胞外的蛋白質,以 及可以供應用於工業、農業、食品工業、環境工業、水產 業和畜牧業的酵素,尤其是醫藥用蛋白質和胜肽,諸如干 擾素、人類和動物激素、免疫性抗原和抗體。 可被使用於本發明的宿主細胞可以是原核或真核生物 15細胞’且可以是未經轉形/轉染的細胞,或是已被至少一種 非本文中所揭露的特定核酸序列的其他的重組型核酸序列 轉形/轉染的細胞。 適用於本發明的原核生物細胞包括,但不限於:彳 自下列的細胞:細菌,例如大腸桿菌(五· 、枯草椁菌 20 (万沉⑹似⑽办⑹以)、乳桿菌屬物種5*ρ·)、鍵徵 菌屬物種(Streptomy 577·)以及沙門氏傷寒桿菌 (Salmonella typhi);轰綠豫(Cyanobacteria) ·,故电儀 (Aci/nomyceia)等等。 適用於本發明的真核細胞包含,例如:真菌細胞、原 37 1296285 生動物(protozoa)細胞、植物細胞、昆蟲細胞、動物細胞以 及人類細胞。合適的真菌細胞實例是酵母菌細胞,諸如麵 包酵母菌απνζϋ幻或嗜甲醇酵母菌 (Ρί(:/Η·α 的細胞。合適的植物細胞是那些衍生自裸 5 子植物(gynosperms)或被子植物(angiosperms)的,以單子葉 植物(monocots)與雙子葉植物(dicots)為佳,特別是作物 (crops),而且是衍生自這些植物的根、莖、葉或分生組織 (medstem),並以原生質體(pr〇t〇plasts)或癒合組織(callus) 丨 的形式被培養。合適的昆蟲細胞的實例是果繩S2細胞以及 10衍生自秋行軍蟲也)的Sf21細胞與Sf9細 胞。合適的動物細胞可以是培養的細胞或活體内細胞,較 佳是衍生自脊椎動物,更佳為衍生自哺乳動物,並且是衍 生自這些動物的器官或組織,諸如腎臟、肝臟、肺臟、卵 巢、乳房、皮膚、骨絡、血液。動物細胞的代表例包括: 15 CHO、COS、BHK、HEK_293、HeLa、NIH3T3、VERO、 MDCK、MOLT-4、Jurkat、K562、HepG2等等。 _ 在本發明的一個較佳具體例中,該重組型宿主細胞是BLAST analysis of the GenBank/EMBL, SWISSPROT, and PIR databases predicted that the WSSV id coding region contained the Cys2/His2-type zinc finger motif. This element has a role in DNA binding, and its presence suggests that the WSSV may produce a function as a 20 transcription factor. The 2 kbp promoter region of WSSV W was cloned [it was amplified by PCR using primer 126-2k-F (SEQ ID NO: 17) and primer 126-R (SEQ ID NO: 16) The nucleotide sequence of [exit] is shown in Sequence Identification Number: 29. The nucleotide sequence of the WSSV coding region and the putative amino acid sequence encoded by 31 1296285 are shown in Sequence Identification Number: 30 and Sequence Identification Number: 31, respectively. In accordance with the above, the present invention provides an isolated Wssv very early promoter-regulatory region consisting essentially of a nuclear nucleoside sequence selected from the group consisting of: (1) a sequence identification number: a nucleotide sequence of 29; (ii) a 5, truncated fragment of the nucleotide sequence of (1) (5, seven unsecated fragments) 'It has at least 3 of the sequence identification number: 29 92 nucleotide residues; 10 (丨丨丨) a nucleic acid sequence which is composed of a white spot virus (WSSV) genomic DNA as a template and a primer set having a forward primer and a reverse primer. Amplification is carried out by a polymerase chain reaction (P〇lymeraSe chain reaction), which is basically composed of a nucleotide sequence selected from the group consisting of sequence identification number: 15 and sequence identification number: π 15 a nucleotide sequence consisting essentially of a nucleoside acid sequence of sequence identification number 16; (iv) - a nucleic acid analog of the nucleotide acid sequence of (1) Nucleic acid analogue), which has the nucleotide sequence of (1) to Approximately 60% less sequence identity and can drive the expression of a target gene operably linked to the nucleic acid analog; (v) - a 5'-truncated fragment of (ii) a nucleic acid analog having at least about 60% sequence identity to the 5'-truncated fragment of exemplified, and 32 I296285 and which can drive the expression of a target gene operably linked to the nucleic acid analog; (vi) - a variant of the nucleotide sequence of (1) which contains at least one conservative substitution and which drives the expression of a target gene operably linked to the variant; (vii) - a variant of the 5'-truncated fragment of (8) which contains at least _ conservation substitutions and which drives the expression of a target gene operably linked to the variant. 10 15 20 According to the invention, when the isolated WSSV very early promoter-regulatory region consists essentially of a 5,_ truncated fragment of the nucleotide sequence of (1), it preferably has a sequence Identify at least 160 nucleotide residues from the 3' end of the number. More preferably, the 5,~ truncated fragment of the nucleotide sequence of (1) has at least 25 桉4 acid residues from the 3' end of the sequence number:29. More preferably, the 5th truncated fragment of the _nuclear (four) sequence has at least 5_nuclear acid base from the end of the column identification number: 29. Preferably, the truncated fragment of the (1) p-acid sequence has at least 1 nucleus: acid residue from the 3' end of 29. According to the present invention, the isolated very early initiation of the amplification reaction is carried out; the introduction of the scorpion and a reverse primer. Cr column identification number: the order of the shirt = the primer is basically composed of - selected from the nuclear singularity shown in the sequence: 17, and the reverse is basically identified by the _ sequence 33 1296285 column The nucleotide sequence of number: 16 is composed. In a preferred embodiment of the present invention, the DNA template is extracted from the Taiwan isolate WSSVT-1, and the sample of the isolate is deposited with the China National Culture Collection under the registration number CCTCC-V96001. 5 According to the present invention, the isolated WSSV very early promoter/peripheral region may also comprise a conservation variant of the nucleotide sequence of sequence identification number: 29 and synthetic analogues [ Such as sequence deletion (deieti〇n), insertion (inserti〇n), inversion (inverison), substitution or addition, but there are 10 pieces of such variants and the like can be similarly The transcription of the sequence at which the trigger bit is downstream and operably linked. In various embodiments, the variants and analogs may be substantially homologous to the term used in the preceding text, or greater than 60% when measured using the algorithm described in the foregoing. , 7〇% to 1〇〇%, at least 1580%, at least 9%, or at least 95% identity. According to the present invention, the isolated WSSV very early promoter-regulatory region can be carried in a performance sputum. As used herein, the term 'sees "a synthetically or recombinantly produced nucleic acid construct that carries a series of nucleic acid elements to permit transcription and translation of a particular nucleic acid within a target cell. A variety of different strategies can be used to supply fragments for combining or combining DNA, and depending on the nature of the terminal of the eight segments, a suitable strategy will be immediately apparent to those skilled in the art. The above-mentioned WSSV very early promoter-regulatory region is capable of driving a heterologous 34 1296285 (translation termination site), an insertion cloning location, an enhancer sequence, and a polyadenylation site. (polyadenylation site), a regulatory sequence, and the like. In addition, the vector of the present invention may comprise a nucleotide sequence relating to one or more restriction endonuclease recognition sites. These sequences are well known to those skilled in the art. Marker genes suitable for use in the present invention include, for example, a dihydrofolate reductase gene for eukaryotic cell culture and a G418 or neomycin resistance gene, Zeocin resistant group 10 for insect cell culture. And, for ampicillin, streptomycine, tetracycline or kanamycine resistance genes for E. coli and other bacterial cultures. In a preferred embodiment of the invention, the recombinant expression vector further comprises a second target gene located downstream of 15 of the other promoter sequence and operably linked to the other promoter sequence, the A promoter sequence may or may not be a wssv very early promoter-regulatory region as disclosed herein. According to the present invention, the first and second target genes independently encode a gene product selected from the group consisting of an enzyme, a therapeutic poly 20 peptide, an epitope, and an antibody. In a preferred embodiment of the invention, the recombinant expression vector is pIZME/WSSV126-2k/V5-EGFP-His. In another preferred embodiment of the invention, the recombinant expression vector is pIZAIE/WSSV126-lk/V5-EGFP-His. 36 1296285, ,, and the type of performance carrier can be used to transform or transfect a beggar, the master of the field. Accordingly, the present invention provides recombinant host cells which are produced by transforming a host cell into a recombinant expression vector of t. It is contemplated that the practice of the invention is not limited to the use of particular host 5 cells. In principle, the present invention can be applied to a wide variety of prokaryotic and eukaryotic donor cells 'including: bacterial cells, yeast cells, fungal cells, plant cells, insect cells, mammalian cells, etc., and can be Used to produce useful ribozymes and RNA transcripts, as well as different kinds of proteins, including proteins present in the cytoplasm or periplasmic space 10, proteins present on the cell membrane or extracellular proteins, and Supply enzymes for the industrial, agricultural, food, environmental, aquaculture and animal husbandry industries, especially pharmaceutical proteins and peptides such as interferons, human and animal hormones, immune antigens and antibodies. The host cell which can be used in the present invention may be a prokaryotic or eukaryotic 15 cell' and may be an untransformed/transfected cell, or another having been subjected to at least one specific nucleic acid sequence not disclosed herein. Recombinant nucleic acid sequence transfected/transfected cells. Prokaryotic cells suitable for use in the present invention include, but are not limited to, cells derived from bacteria such as Escherichia coli (five, Bacillus subtilis 20 (Wan Shen (6) like (10) (6)), Lactobacillus species 5* ρ·), Keystrophy species (Streptomy 577·) and Salmonella typhi (Symonella typhi); Cyanobacteria, Aci/nomyceia and so on. Eukaryotic cells suitable for use in the present invention include, for example, fungal cells, protozoa 37 1296285 protozoa cells, plant cells, insect cells, animal cells, and human cells. Examples of suitable fungal cells are yeast cells, such as baker's yeast απν illusion or methanolophilic yeast ( cells of Ρί(:/Η·α. Suitable plant cells are those derived from gynosperms or angiosperms). (angiosperms), preferably monocots and dicots, especially crops, and derived from the roots, stems, leaves or mestems of these plants, and It is cultured in the form of protoplasts (pr〇t〇plasts) or healing tissues (callus). Examples of suitable insect cells are Sf21 cells and Sf9 cells derived from the fruit line S2 cells and 10 derived from the autumn army insects. The animal cells may be cultured cells or cells in vivo, preferably derived from vertebrates, more preferably from mammals, and are organs or tissues derived from such animals, such as kidneys, liver, lungs, ovaries, breasts. , skin, bone network, blood. Representative examples of animal cells include: 15 CHO, COS, BHK, HEK_293, HeLa, NIH3T3, VERO, MDCK, MOLT-4, Jurkat, K562, HepG2, and the like. In a preferred embodiment of the invention, the recombinant host cell is
Sf9昆蟲細胞。 適用於進行DNA重組技術的宿主細胞的適當培養基以 20及培養條件是生物技術領域中已詳知的。例如,可將宿主 細胞培養在一發酵生物反應器、一搖動燒瓶、一試管、一 微滴定盤或—培養孤中,並且該等宿主細胞的培育可在適 合於該等細胞生長的條件(包括培養溫度、培養基的pH值, 以及培養物的溶氧濃度)下來進行。 38 1296285 最後,本發明提供一用於選殖一WSSV極早期啟動子— 調節區域的引子組,其包含有一順向引子與一反向引子, 該順向引子基本上是由一選自於如序列辨識編號:15與序 列辨識編號:17所示的核苷酸序列當中的核苷酸序列所構 5成,而該反向引子基本上是由一為序列辨識編號:16的核 苷酸序列所構成。 邊引子組可被用來選殖演化上同源於本文中所揭露的 特定序列的WSSV極早期啟動子-調節區域。 可預期到本文中所揭露的所有的材料與方法學均可用 10 來實施本發明。 本發明將就下面實施例來作進一步說明。一個具有本 技蟄中的通常知識的人士會熟悉於許多容許這些實施例以 及在本案揭露内容中所注意到的實施例(它們也應用本發 明的基本的、新穎的或有利的特徵)的修飾的技術和教示。 15因此,本發明的範疇並不受此處或其他地方所列的特定實 施例所限制。 實施例 I·材料與方法 病毒的基因微陣列—晶片的製備 20 草蝦WssV 1994台灣分離株(WSSV Τ_υ(它的基因組 以登錄編號AF4405 70被登錄於NCBI資料庫中)被使用於以 下面所描述的所有實驗中。這個WSSVT〜1分離株已根據布 達佩斯條約而於1996年1月11日被寄存於中國典型培養物 保藏中、(CCTCC,武漢大學,珞珈山,武漢,湖北,430〇72, 39 1296285 中華人民共和國),並且被給予寄存編號CCTCC-V96001 (參見授予郭光雄等人的1^ 5,824,535與1;5 6,190,862)。 WSSV病毒基因微陣列(晶片)是根據WSSV T-1分離株 的基因組而被設計的。簡要而言,各個晶片含有532個預測 5的WSSV ORFs以及草蝦/5-肌動蛋白基因的一個部分序 列。在進行使用衍生自這532個ORFs的特異性引子的聚合 酶連鎖反應(PCR)之後,對於各個WSSVORFs而言具有200 至600 bp的擴增產物大小的PCR產物以三重複方式被打點 在預塗覆的玻璃載玻片(U-Vision Biotech Inc·,臺灣)上, 10 而有關蝦(草蝦肌動蛋白基因也是作3個複製。蝦/5-肌 動蛋白基因當作一正對照組,且被用來正規化載玻片之間 的數據。 製備病毒微陣列的細節被描述於各種不同的文獻中, 參見’例如H.-C. Wang,et al· “DNA microarrays of the white 15 spot syndrome virus genome: genes expressed in the gills of infected shrimp,” Marine Biotechnology,付梓中。 病毒基因微陣列-標的的製備 有關於病毒接種物的製備以及病毒攻毒試驗(viral challegene trial)的插作程序被描述於从乃仍· α/. (*/999), 20 Dis· Aquat. Org·,38 (2),107-114 中。 用來進行CHX (Sigma)處理與病毒攻毒試驗的養殖的 無WSSV蝦(草蝦)是由行政院農業委員會水產試驗所的東 港水產貫驗中心(Tung-Kang Marine Laboratory,Taiwan Fisheries Research Institute)慷慨提供。在實驗期間當中,在 40 1296285 25C的環溫下,具一體重為3545公克的蝦被養殖於8個含 有無菌的33 ppt (千分之一)海水的1000公升的FRP (纖維強 化塑膠)槽中。 WSSV接種物是製備自經實驗感染的蝦(草蝦)的集合 5的組織。為了鑑定WSSVIE基因,在病毒攻毒試驗之前2小 時’ WSSVT-1感染的蝦藉由肌肉内注射被處理以不同劑量 的CHX (12.5 mg/kg、62.5 mg/kg與250 mg/kg體重,製備於 2〇%乙醇中)。對照組蝦只被注射以2〇%乙醇。 於病毒攻毒試驗中,經CHX與20%乙醇預處理的蝦分 10別地以一個〇·9% NaCl溶液予以假感染(m0Ck-infected)或藉 由肌肉内注射被感染以一劑量為5〇 pL/10 g體重的WSSV接 種物(製備於0.9% NaCl溶液中)。由於鰓組織是WSSV感染 的一個主要標的(C.-F· Lo, ef αί· (J996),Dis. AquaL Org·, 27, 215-225·,md H,C. Liu,et al· (1997),Dis, Aquat· Org·, 15 53-72),在感染8小時之後(hpi),經假感染與WSSV-感染 的瑕的鰓組織被收集並被立即地冷凍在液態氮内直到RNA 萃取之時。 依據製造商的操作程序,使用一Rneasykit(Qiagen)而 從所收集的蝦鰓組織來收穫總RNA (total RNA)。為了製造 20 cDNA標的物,依據製造商的操作指南,使用一個CyScribe First cDNA Labeling kit (Amersham Bioscience)而將 RNA樣 品(2〇 kg)螢光標示以Cy3dUTP。之後,使用Microcon YM-30管柱(Amicon)來移除未被併入的游離核苷酸。由此 而得到的Cy3 -標示的cDNA被濃縮,並在隨後的實驗中被用 41 1296285 作為微陣列標的物。 病毒基因m車列-探針I標的物的雜交、掃描與統計學分析 上面所製備的Cy3-標示的cDNA標的物被引至與位在 WSSV微陣列内的所有1:^八點進行雜交反應,繼而使用一 5 個共軛聚焦雷射掃描儀(confocal laser scanner,GeneTAC™ LS IV Microarray Sc麵er,Genomic Solutions)來掃描微陣 列。被掃描的螢光強度是藉由GenePix 3·〇 (Axon Instruments)來定量。 有關那些被結合至微陣列探針的轉錄本,它們被偵測 10到的成號強度疋精由扣除背景訊號位準(background signal levels)而被轉變成為大概的絕對表現量的測量值。正對照組 (草嘏石-肌動蛋白基因)的訊號位準被用來正規化不同陣列 之間的病毒基因表現結果。WSSV的基因表現是藉由以經 CHX-預處理的WSSV-感染的晶片上的被正規化的基因表 I5 現位準相對於經假感染的晶片内的對應基因的正規化比率 (normalized ratios)來繪圖而被決定。 藉由CHX-不敏感的基因的RT-PCR分析來確認微陣列結果 關於處在CHX處理的最高位準(250 mg/kg體重)下的微 陣列結果,那些在WSSV-感染的樣品内的強度的中間位準 20 要比在假感染的樣品内所具者至少高1.5倍的ORFs被進行 反轉錄酶-聚合酶連鎖反應(RT-PCR)。 於RT-PCR分析中,模板是製備自原始批次的總RNA (亦即來自經250 mg/kg CHX-預處理的WSSV-感染的蝦)的 樣品,以及一另外批次的RNA (萃取自以20%乙醇預處理的 42 1296285 WSSV-攻毒的蝦)。該等RNA樣品(20 pg)於37°C下被處理以 不含核糖核酸酶(Rnase)的去氧核糖核酸酶I (DNase I, Roche)歷時1小時以便除去位於所製備的總RNA樣品内的 任何病毒基因組DNA污染物。一分裝部分的總RNA (〜10 pg) 5 藉由使用配於一為20 μί的反應混合物内的Superscript II反 轉錄酶(Invitrogen)與募(dT)引子而被用來合成第一股 cDNA。在RT反應之後,一分裝部分(2 pL)的反應產物(含有 大約1 pg的cDN A)以對應於那些被表現於CHX-預處理的被 感染的蝦内的WSSV基因(亦即,被顯示於微陣列分析結果 10中的該等IE基因候選物)的特異性引子組來進行pCR。作為 CHX處理組的一個正對照組,亦以一基因_特異性引子組 dnapolF/dnapolR (表1)來進行PCR,該引子組是根據一先前 報導的WSSV遲發早期基因,亦即办叩W,而被設計出(乙丄Sf9 insect cells. Suitable media for host cells for performing DNA recombination techniques are well known in the art of biotechnology. For example, the host cells can be cultured in a fermentation bioreactor, a shake flask, a test tube, a microtiter plate, or a cultured orphan, and the host cells can be cultured under conditions suitable for the growth of the cells (including The culture temperature, the pH of the culture medium, and the dissolved oxygen concentration of the culture are carried out. 38 1296285 Finally, the present invention provides a primer set for culturing a WSSV very early promoter-regulatory region, comprising a forward primer and a reverse primer, the forward primer being substantially selected from the group consisting of The sequence identification number: 15 and the nucleotide sequence of the nucleotide sequence shown in the sequence identification number: 17 are composed of 5 nucleotides, and the reverse primer is basically a nucleotide sequence of sequence identification number: 16. Composition. The side primer set can be used to select a WSSV very early promoter-regulatory region that is evolutionarily homologous to the particular sequence disclosed herein. It is contemplated that all of the materials and methodologies disclosed herein may be used to practice the invention. The invention will be further illustrated by the following examples. A person having ordinary knowledge in the art will be familiar with many modifications that allow these embodiments, as well as the embodiments noted in the present disclosure, which also apply the basic, novel or advantageous features of the present invention. Technology and teaching. Therefore, the scope of the invention is not limited by the specific embodiments set forth herein or elsewhere. Example I·Materials and Methods Gene microarray of virus-wafer preparation 20 Grass shrimp WssV 1994 Taiwan isolate (WSSV Τ_υ (its genome is registered in the NCBI database under accession number AF4405 70) was used in the following In all the experiments described, this WSSVT~1 isolate has been deposited with the Chinese Type Culture Collection on January 11, 1996 according to the Budapest Treaty (CCTCC, Wuhan University, Lushan, Wuhan, Hubei, 430〇) 72, 39 1296285 People's Republic of China), and was given the registration number CCTCC-V96001 (see 1^5,824,535 and 1; 5 6,190,862 granted to Guo Guangxiong et al.) WSSV viral gene microarray (wafer) is based on WSSV T- 1 The genome of the isolate was designed. Briefly, each wafer contained 532 predicted 5 WSSV ORFs and a partial sequence of the grass shrimp/5-actin gene. The specificity derived from these 532 ORFs was used. After the polymerase chain reaction (PCR) of the sex primer, the PCR product having an amplification product size of 200 to 600 bp for each WSSVORFs was spotted in a pre-coated manner in a three-fold manner. Glass slides (U-Vision Biotech Inc., Taiwan), 10 and related shrimps (the grass shrimp actin gene is also used for 3 replicates. The shrimp/5-actin gene is used as a positive control group and is Used to normalize data between slides. Details of preparing viral microarrays are described in various literatures, see 'eg H.-C. Wang, et al· DNA microarrays of the white 15 spot syndrome virus Genome: genes expressed in the gills of infected shrimp," Marine Biotechnology, Fu Xizhong. Preparation of viral gene microarrays - the preparation of the virus inoculum preparation and viral challegene trial is described in From still to α/. (*/999), 20 Dis· Aquat. Org·, 38 (2), 107-114. Cultured WSSV-free shrimp used for CHX (Sigma) treatment and virus challenge tests (Grass shrimp) was generously provided by the Tung-Kang Marine Laboratory (Taiwan Fisheries Research Institute) of the Fisheries Research Institute of the Executive Yuan Agricultural Committee. During the experimental period, at the temperature of 40 1296285 25C With a weight of 3545 g of shrimp farming in 8 containing sterile 33 ppt (one thousandth) of 1000 liters of water FRP (fiber-reinforced plastics on) slots. The WSSV inoculum is the tissue prepared from the collection 5 of experimentally infected shrimp (grass shrimp). To identify the WSSVIE gene, WSSVT-1 infected shrimp were treated with different doses of CHX (12.5 mg/kg, 62.5 mg/kg and 250 mg/kg body weight) by intramuscular injection 2 hours prior to the virus challenge test. In 2% ethanol). Control shrimp were injected with 2% ethanol. In the virus challenge test, shrimp pretreated with CHX and 20% ethanol were randomly infected with a 〇·9% NaCl solution (m0Ck-infected) or infected by intramuscular injection at a dose of 5 〇pL/10 g body weight WSSV inoculum (prepared in 0.9% NaCl solution). Because sputum tissue is a major target of WSSV infection (C.-F· Lo, ef αί· (J996), Dis. AquaL Org·, 27, 215-225·, md H, C. Liu, et al· (1997) ), Dis, Aquat· Org·, 15 53-72), after 8 hours of infection (hpi), pseudo-infected and WSSV-infected sputum sputum tissues were collected and immediately frozen in liquid nitrogen until RNA extraction When. Total RNA was harvested from the collected shrimp tissue using a Rneasykit (Qiagen) according to the manufacturer's protocol. To make the 20 cDNA target, the RNA sample (2 〇 kg) was fluorescently labeled with Cy3dUTP using a CyScribe First cDNA Labeling kit (Amersham Bioscience) according to the manufacturer's instructions. Thereafter, a Microcon YM-30 column (Amicon) was used to remove unincorporated free nucleotides. The Cy3-labeled cDNA thus obtained was concentrated, and in the subsequent experiments, 41 1296285 was used as the microarray target. Hybridization, scanning and statistical analysis of the viral gene m-column I target The Cy3-labeled cDNA target prepared above was introduced to hybridize with all 1:8 points in the WSSV microarray. Then, a five conjugated laser scanner (GenetaCTM LS IV Microarray Sc surface er, Genomic Solutions) was used to scan the microarray. The intensity of the scanned fluorescence was quantified by GenePix 3® (Axon Instruments). For those transcripts that are bound to the microarray probes, they are detected as 10 to the intensity of the sputum, which is converted to a measure of approximate absolute performance by subtracting the background signal levels. The signal level of the positive control group (grass stone-actin gene) was used to normalize viral gene expression results between different arrays. The gene expression of WSSV is based on the normalized ratios of the normalized gene table I5 on the CHX-pretreated WSSV-infected wafer relative to the corresponding gene in the pseudo-infected wafer. It was decided to draw. RT-PCR analysis of CHX-insensitive genes confirmed microarray results for microarray results at the highest level of CHX treatment (250 mg/kg body weight), those in WSSV-infected samples The intermediate level 20 is reverse transcriptase-polymerase chain reaction (RT-PCR) for ORFs that are at least 1.5 times higher than those in the pseudo-infected sample. In the RT-PCR analysis, the template was prepared from the original batch of total RNA (ie, from 250 mg/kg CHX-pretreated WSSV-infected shrimp) and an additional batch of RNA (extracted from 42 1296285 WSSV-attacked shrimp pretreated with 20% ethanol). The RNA samples (20 pg) were treated at 37 ° C with ribonuclease (Rnase)-free DNase I (Roche) for 1 hour to remove the total RNA sample prepared. Any viral genomic DNA contaminant. A portion of total RNA (~10 pg) 5 was used to synthesize the first strand of cDNA by using Superscript II reverse transcriptase (Invitrogen) and a (dT) primer in a 20 μί reaction mixture. . After the RT reaction, a portion (2 pL) of the reaction product (containing approximately 1 pg of cDN A) was dispensed to correspond to those WSSV genes that were expressed in the infected shrimp treated with CHX-pretreatment (ie, The specific primer set of the IE gene candidates shown in the microarray analysis result 10 was subjected to pCR. As a positive control group of the CHX treatment group, PCR was also carried out using a gene-specific primer set dnapolF/dnapolR (Table 1) based on a previously reported early WSSV late gene, ie, W And was designed to
Chen et al· (2002),Virology,301,136-147)。 15Chen et al. (2002), Virology, 301, 136-147). 15
43 1296285 表1.被使用於藉由微陣列與CHX處理來篩選wssv IE基因的引子 ORF/基因 引子序列(5’- 3’) WSSV T-1 基 因組序列座標 擴增產物 大小(bp) ORF126"W 126F: gactctacaaatctctttgcca (序列辨識 編號:1) 126SP1: ctacctttgcaccaattgctag (序列辨 識編號:2) 65729—65750 66209—66230 502 bp ORF242/^2 242F1: ataccaacaaccccagaa (序列辨識編 號:3) 242R1: atggggcgggatacaaaa (序列辨識 編號:4) 131117—131134 131332—131349 233 bp 0RF418/^3 418F1: gctggaggaggcttgttgat (序列辨識 編號:5) 418R1: gggccagaaatgccttacag (序列辨識 編號:6) 242832—242851 243081—243100 269 bp DNA pol dnapolF: tgggaagaaagatgcgagag (序歹】J 辨 識編號:7) dnapolR: ccctccgaacaacatctcag (序歹辨 識編號:8) 26292-^26311 26858 — 26877 586 bp VP28 vp28F: ctgctgtgattgctgtattt (序列辨識編 號:9) vp28R: cagtgccagagtaggtgac (序列辨識 編號:10) 278914—278933 279450 — 279468 555 bp 基因間的 IC-F2: cagactattaatgtacaagtgcg (序列辨 識編號:11) IC-R3: gaatgattgttgctggttagaacc (序歹辨 識編號:12) 126597-^126619 125494—125517 1126 bp 蝦/3 -肌動蛋白 肌動蛋白 FI: gaygayatggagaagatctgg (序 列辨識編號:13) 肌動蛋白 Rl: ccrgggtacatggtggtrcc (序 列辨識編號:14) — 686 bp43 1296285 Table 1. Primer ORF/gene primer sequence (5'-3') used to screen the wssv IE gene by microarray and CHX treatment WSSV T-1 genome sequence coordinate amplification product size (bp) ORF126" W 126F: gactctacaaatctctttgcca (SEQ ID NO: 1) 126SP1: ctacctttgcaccaattgctag (SEQ ID NO: 2) 65729—65750 66209—66230 502 bp ORF242/^2 242F1: ataccaacaaccccagaa (SEQ ID NO: 3) 242R1: atggggcgggatacaaaa (Sequence Identification Number :4) 131117—131134 131332—131349 233 bp 0RF418/^3 418F1: gctggaggaggcttgttgat (SEQ ID NO: 5) 418R1: gggccagaaatgccttacag (SEQ ID NO: 6) 242832—242851 243081—243100 269 bp DNA pol dnapolF: tgggaagaaagatgcgagag (Order歹] J identification number: 7) dnapolR: ccctccgaacaacatctcag (serial identification number: 8) 26292-^26311 26858 — 26877 586 bp VP28 vp28F: ctgctgtgattgctgtattt (sequence identification number: 9) vp28R: cagtgccagagtaggtgac (sequence identification number: 10) 278914 —278933 279450 — 279468 555 bp Intergenic IC-F2: cag Actattaatgtacaagtgcg (SEQ ID NO: 11) IC-R3: gaatgattgttgctggttagaacc (Serial Identification Number: 12) 126597-^126619 125494-125517 1126 bp Shrimp/3 - Actin Actin FI: gaygayatggagaagatctgg (Serial Identification Number: 13) Actin Rl: ccrgggtacatggtggtrcc (SEQ ID NO: 14) — 686 bp
作為一用以檢查WSSV基因組DNA污染物的品質管 制,亦以未進行反轉錄作用的CHX-預處理的WSSV-感染的 RNA樣品來進行PCR。擴增自WSSV基因組DNA的PCR產物 5用來作為一PCR正對照組,並且也被用來作為一相關的大 小標記。 啟動子活性分析 對於以RT-PCR而被確認的各個WSSV IE基因候選物, 一個短暫報導基因分析(transient reporter assay)被執行。關 44 1296285 於這俩分析,Sf9昆蟲細胞(Invitrogen)被數個裡面各別地攜 帶有一個EGFP報導基因的啟動子分析質體所轉染。 作為這個分析的一個起始點,一質體pIZAIE/V5-His是 從一商業上可取得的質體pIZ/V5-His(Invitrogen),藉由刪除 5 坐落在多重選殖位址(MCS)之前的0pIE2 (OpMNPV化2)啟 動子改質而得。隨後,一EGFP基因(BD Biosciences)被插入 至pIZAIE/V5-His的MCS内以便生成一個第一衍生質體 pIZAIE/V5-EGFP-His。 之後,藉由使用在它們的5,端處含有適當的限制内切 10 酶辨識位址的引子(參見表2)的PCR,而從WSSV基因組 DNA擴增出各個WSSV IE基因候選物的5’未轉譯區域(5, UTRs)的部分(〜1 kbp)。使用GFX PCR產物純化套組(Roche) 來純化所形成的各個PCR產物,以限制内切酶予以消化, 並接而予以插入至pIZAIE/V5-EGFP-His MCS内的EGFP基 15因之前。所形成的質體被命名為 pIZAIE/WSSVx/V5-EGFP-His,其中 “X” 代表一個藉由 RT-PCR分析而被選出的0RF。 一個藉由將EGFP基因選殖至質體PIZ/V5-His内而被建 構出的質、體pIZ/V5-EGFP-His用來作為正對照組質體,而一 2〇 對應的AIE質體,亦即pIZME/V5-EGFP-His用來作為一負對 照組。另一個負對照組質體是藉由將EGFP基因與WSSV 啟動子區域至插入質體pIZAIE/V5-EGFP-His内來生 成pIZME/WSSVdnapol/V5-EGFP-His而被建構出。對於一 個提供正訊號(positive signal)的啟動子序列候選物,它的反 45 1296285 向序列被用來構築一個被命名為 pIZME/WSSVxrev/V5-EGFP-His 的額外對照組質體。 最後,除了這些1 kbp的順向與反向質體之外,各卷 可虽有 一質體表現一高位準的EGFP時,它的啟動子藉由構築—個 5 由一段2 kbp順向片段所驅動的EGFP-報導基因質體而被進 一步分析。所有這些選殖株的正確性係透過DNA定序予以 確認。該等用於這些質體的構築之引子被列示於表2中。As a quality control for examining WSSV genomic DNA contaminants, PCR was also performed on CHX-pretreated WSSV-infected RNA samples without reverse transcription. The PCR product 5 amplified from WSSV genomic DNA was used as a positive control for PCR and was also used as a related size marker. Promoter Activity Assay For each WSSV IE gene candidate identified by RT-PCR, a transient reporter assay was performed. Off 44 1296285 In both analyses, Sf9 insect cells (Invitrogen) were transfected with several promoters with an EGFP reporter gene. As a starting point for this analysis, the plastid pIZAIE/V5-His is a commercially available plastid pIZ/V5-His (Invitrogen), which is located at the multiple colonization site (MCS) by deletion 5 The previous 0pIE2 (OpMNPV 2) promoter was remodeled. Subsequently, an EGFP gene (BD Biosciences) was inserted into the MCS of pIZAIE/V5-His to generate a first derivative plastid pIZAIE/V5-EGFP-His. Thereafter, 5' of each WSSV IE gene candidate was amplified from WSSV genomic DNA by using PCRs containing primers (see Table 2) with appropriate restriction endonuclease 10 recognition sites at their 5' ends. The portion of the untranslated region (5, UTRs) (~1 kbp). Each of the resulting PCR products was purified using a GFX PCR product purification kit (Roche) to limit digestion by endonuclease and then inserted into the EGFP-based 15 factor in pIZAIE/V5-EGFP-His MCS. The resulting plastid was named pIZAIE/WSSVx/V5-EGFP-His, where "X" represents an ORF selected by RT-PCR analysis. A plastid, pIZ/V5-EGFP-His constructed by culturing the EGFP gene into the plastid PIZ/V5-His was used as a positive control plastid, and a 2 〇 corresponding AIE plastid That is, pIZME/V5-EGFP-His was used as a negative control group. Another negative control plastid was constructed by introducing the EGFP gene and the WSSV promoter region into the plastid pIZAIE/V5-EGFP-His to generate pIZME/WSSVdnapol/V5-EGFP-His. For a promoter sequence candidate that provides a positive signal, its reverse 45 1296285 sequence was used to construct an additional control plastid named pIZME/WSSVxrev/V5-EGFP-His. Finally, in addition to these 1 kbp forward and reverse plastids, each volume can have a high level of EGFP, and its promoter is constructed by a 5 segment of a 2 kbp directional fragment. The driven EGFP-reported gene plastid was further analyzed. The correctness of all these strains was confirmed by DNA sequencing. These primers for the construction of these plastids are listed in Table 2.
表2·被用來構築用於啟動子活性分析的短暫表現載體的引子Table 2. Injectors used to construct transient expression vectors for promoter activity analysis
質體 引子序列(5’- 3’)/限制酶* 擴 大小(bp、 ρΙΖΔΙΕ/WSS V126-1 k/V5-EGFP-His F: cg£^Mi£gagatcctagaaagaggagtg (序列辨 識編號·· 15)/EcoRl R: ccg£i££^£cttgagtggagagagagagc (序列辨 識編號: 997 pIZAIE/WSSV126-2k/V5^EGFP-His F: cggMli£gatgatggtgatgtttctagg (序列辨識 編號·· 17)/EcoRl R: ccg£l£^£cugagtggagagagagagc (序列辨 識編號:16)/XhoI 2063 pIZAIE/WSSV126rev/V5-EGFP-His F: cgg^£cttgagtggagagagagagc (序列辨 識編號:18)/£coRl R: ccgctceaegacatcctaeaaaeaeeagtg (^ ^»| 辨識編號:19)/X/ioI 997 pIZAIE/WSSV242/V5>EGFP-His F: eeeetaccetcttcaacatcttcttgttcg 識編號:20)ΑίΓρηΙ R: ataagaatgcsecceccatsaaeatctctgegaaatg (序列辨識編號:21)/Λ^ίΙ 987 pIZAIE/WSSV418/V5-HGFP-His F: cseaattcetcecacatetgtctaaacttc 識編號:22)/£cMI R: ccectceaecaacaaecctcctccaecc 識編號:23) /X/^I 841 pIZAIE/WSSVdnapol/V5-EGFP-His F: tagaectcacttctccteacactcttsactsat H 辨識編號·· 24)/Sacl R: gtggaagagggtgatggagctggagatgatcatc (序 列辨識編號:25) 571 :該等引子的限制酶切割位址被劃底線。 10 為了進行DNA轉染,Sf9昆蟲細胞被播種於一個24井培 養盤(3xl05細胞/井)内,並且於27°C下在Sf-900 II SFM無 46 1296285 血清的培養基(Invitrogen)内生長過夜。質體DNA以TE緩衝 液(pH 8.0)予以稀釋至1 pg/pL,以及sf9細胞的脂質體媒介 的轉染(1 gg的質體DNA/井)是依據製造商的操作指南使用The plastid primer sequence (5'-3')/restriction enzyme* is small (bp, ρΙΖΔΙΕ/WSS V126-1 k/V5-EGFP-His F: cg£^Mi£gagatcctagaaagaggagtg (sequence identification number·· 15)/ EcoRl R: ccg£i££^£cttgagtggagagagagagc (Catalog ID: 997 pIZAIE/WSSV126-2k/V5^EGFP-His F: cggMli£gatgatggtgatgtttctagg (Serial Identification Number·· 17)/EcoRl R: ccg£l£^ £cugagtggagagagagagc (SEQ ID NO: 16)/XhoI 2063 pIZAIE/WSSV126rev/V5-EGFP-His F: cgg^£cttgagtggagagagagagc (Serial Identification Number: 18)/£coRl R: ccgctceaegacatcctaeaaaeaeeagtg (^ ^»| Identification Number: 19) /X/ioI 997 pIZAIE/WSSV242/V5>EGFP-His F: eeeetaccetcttcaacatcttcttgttcg ID: 20) ΑίΓρηΙ R: ataagaatgcsecceccatsaaeatctctgegaaatg (Sequence ID: 21)/Λ^ίΙ 987 pIZAIE/WSSV418/V5-HGFP-His F: cseaattcetcecacatetgtctaaacttc Identification number: 22) / £cMI R: ccectceaecaacaaecctcctccaecc ID: 23) /X/^I 841 pIZAIE/WSSVdnapol/V5-EGFP-His F: tagaectcacttctccteacactcttsactsat H Identification number·· 24)/Sacl R: gtggaagagggtga Tggagctggagatgatcatc (SEQ ID NO: 25) 571: The restriction enzyme cleavage site of these primers is underlined. 10 For DNA transfection, Sf9 insect cells were seeded in a 24-well culture dish (3xl05 cells/well) and grown overnight at 27 °C in Sf-900 II SFM without 46 1296285 serum medium (Invitrogen). . The plastid DNA was diluted to 1 pg/pL in TE buffer (pH 8.0), and the liposome vector of sf9 cells was transfected (1 gg plastid DNA/well) according to the manufacturer's protocol.
Cellfectin Reagent (Invitrogen)來進行。在轉染 72 小時之 5後,在一 Olympus 1X71倒立營光顯微鏡(inverted fluorescence microscope)下觀察EGFP螢光訊號,並且使用 一 Olympus DP50 數位顯微鏡照相機(digital microscope camera)來作拍照紀錄。在那個時候,收穫並且溶解細胞。 Φ 從各井而因此得到的細胞溶胞產物被調整成一等量的 10 總蛋白’並藉由西方墨點分析法(Western blotting)來分析 EGFP。關於西方墨點分析法,各個細胞溶胞產物的總蛋白 在15% SDS-PAGE上被分開,轉移至一PVDF膜(Osmonics) 上’並使用抗-EGFP單株抗體(B-2, Santa Cruz Biotechnology)或抗-人類/3 -肌動蛋白多株抗體(η>496, 15 Santa Cruz Biotechnology)來作探針檢測。墨點(blots)是使用 一增強的化學冷光(enhanced chemiluminescent-light,ECL) _ 偵測套組(detection kit)(NEN Life Sciences)而被顯像,其中 被結合以辣根過氧化酶(horseradish peroxidase)的山羊抗-小鼠IgG或山羊抗-兔IgG被用來當作一種二級抗體 20 (secondary antibody) 〇 製作極早期基因轉錄本的5’與3’端點的圖譜 極早期基因轉錄本的5’和3’區域是藉由cDNA 5,/3,端 的快速擴增(rapid amplification)而被獲得(M.A. Fro/憤⑽d al·,(1988),Proc· Natl· Acad· Sci· USA· 85, 8998-9002),這便 47 1296285 用到一種商業的5,/3, RACE套組(Roche),該套組具有一禽 骨髓胚細胞過多病毒(avian myeloblatosis virus,AMV)反轉 錄酶(Roche,被包含於該套組中)。在這個研究中被用於5,/3, RACE分析的RNA樣品是從被WSSV感染24 h後的蝦體予以 5 分離出,並接而以不含RNase的DNase I (Roche)予以處理。 被用於cDNA 5’/3’端的快速擴增的適當基因-特異性引子被 列示於表3中。最終的擴增產物被選殖至pGEM-T Easy載體 (Promega)内並被定序。插入物的序列與WSSV基因組DNA 的序列進行比較。 10 表3·用於ORF126 5’ RACE與3’ RACE的特異性引子 _ 引子序列(5’-3’)_ 用法Cellfectin Reagent (Invitrogen) is coming. After 72 hours of transfection, the EGFP fluorescence signal was observed under an Olympus 1X71 inverted fluorescence microscope and an Olympus DP50 digital microscope camera was used for photo recording. At that time, harvest and dissolve the cells. Φ The cell lysate thus obtained from each well was adjusted to an equal amount of 10 total protein' and EGFP was analyzed by Western blotting. For Western blot analysis, the total protein of each cell lysate was separated on a 15% SDS-PAGE, transferred to a PVDF membrane (Osmonics) and used anti-EGFP monoclonal antibody (B-2, Santa Cruz) Biotechnology) or anti-human/3-actin polyclonal antibody (η > 496, 15 Santa Cruz Biotechnology) for probe detection. Blots were visualized using an enhanced chemiluminescent-light (ECL) _ detection kit (NEN Life Sciences), which was combined with horseradish peroxidase (horseradish) Peroxidase goat anti-mouse IgG or goat anti-rabbit IgG was used as a secondary antibody to produce a very early gene transcription of the 5' and 3' endpoints of very early gene transcripts. The 5' and 3' regions of the present are obtained by rapid amplification of the cDNA 5, /3, (MA Fro / anger (10) d al ·, (1988), Proc · Natl · Acad · Sci · USA · 85, 8998-9002), this 47 1296285 uses a commercial 5,/3, RACE kit (Roche) with avian myeloblatosis virus (AMV) reverse transcriptase (Roche, included in the kit). The RNA samples used in this study for 5,/3, RACE analysis were isolated from shrimps infected 24 hours after WSSV infection and then treated with RNase-free DNase I (Roche). Suitable gene-specific primers for rapid amplification of the 5'/3' end of the cDNA are listed in Table 3. The final amplified product was cloned into the pGEM-T Easy vector (Promega) and sequenced. The sequence of the insert is compared to the sequence of the WSSV genomic DNA. 10 Table 3. Specific primers for ORF126 5' RACE and 3' RACE _ primer sequence (5'-3')_ usage
126SP1: ctacctugcaccaattgctag (序列辨識編號:2) 5, RACE126SP1: ctacctugcaccaattgctag (sequence identification number: 2) 5, RACE
126SP2: gtacagtactgtccatgtcgat (序列辨識編號:26) 5, RACE126SP2: gtacagtactgtccatgtcgat (sequence identification number: 26) 5, RACE
126SP3: cctcttcatcacctcaatacc (序列辨識編號:27) 5, RACE126SP3: cctcttcatcacctcaatacc (SEQ ID NO: 27) 5, RACE
128SP1: gagactgatcgacatggacagtac (序列辨識編號:28) 35 RACE 藉由RT-PCR的WSSV極早期基因轉錄本的暫時性分析 WSSV-攻毒的蝦(草蝦)在〇 hpi(也就是在感染之前的時 刻)以及在2、4、6、8、12、18、24、36、48、60與72 hpi 被採樣。總RNA是從在各個時間點所收穫的蝦的腹足被萃 15取出,以TRIzol Reagent (Invitrogen)予以純化,並接而以不 含RNase的DNase I (Roche)來處理以便移除任何殘留的 DNA。第一股cDNA的合成是使用募(dT)引子來執行,並且 2 μί (〜1 gg)的cDNA於一含有一適當引子組(參見表^的 50-μί反應混合物内進行PCR。為作比較,WSSV心與 2〇叩2(§基因的片段亦分別地以引子組dnapolF/dnapolR與 vp28F/vp28R而自相同的模板被擴增出。一個蝦万_肌動蛋 48 1296285 白引子組,肌動蛋白F1/肌動蛋sR1,被用來作為RNA品質 與擴增效率的一個内部對照組。為了確認在該等RNA樣品 内不存在有WSSVDNA污染物,一WSSV基因組DNA-特異 性引子組,IC-F2/IC-R3 (它們是係衍生自WSSV基因組的一 5個基因間的區域),亦被用來作為一個品質對照組。該等被 用來擴增標的ORF/基因序列的引子組被列示於表1中。 極早期基因啟動子與編碼區域的分析 根據WSSV T-1的基因組(NCBI登錄編號·· AF440570), 該等ORFs以及該等ORFs的上游區域的核苷酸序列是使用 10 電腦程式NNPP (Reese,M.G·, EecKman,F.H·,1995· New neural network algorithms for improved eukaryotic promotor site recognition. In: The seventh international genome sequencing and analysis conference. Hilton Head Island, S. C.; M.G. Reese, et al. (1996), Large scale sequencing 15 specific neural networks for promotor and splice site recognition. In: Hunter, L., Klein. T.E. (Eds.), Biocomputing: Proceedings of the 1996 Pacific symposium. World Scientific Publishing,Singapore)以及GenBank/EMBL、SWISSPROT、 PIR和EMBOSS資料庫而被分析的。 20 Π ·結果 使用微陣列與CHX處理以篩選WSSVIE基因 當WSSV DNA (ORF/基因)微陣列被用來檢查病毒基因 表現時,於WSSV-感染的蝦體内存在的蛋白合成抑制劑 CHX被預期會導致病毒極早期基因的RNA轉錄本的特定蓄 49 1296285 積。這是因為,雖然所有其他病毒基因的轉錄會需要病毒 蛋白作為轉錄因子,該等蛋白的合成由於CHX的存在而已 受到抑制。128SP1: gagactgatcgacatggacagtac (SEQ ID NO: 28) 35 RACE Temporary analysis of WSSV very early gene transcripts by RT-PCR WSSV-attacked shrimp (grass shrimp) at 〇hpi (that is, at the time before infection) And samples are taken at 2, 4, 6, 8, 12, 18, 24, 36, 48, 60 and 72 hpi. Total RNA was removed from the ascites of shrimp harvested at various time points, purified by TRIzol Reagent (Invitrogen), and then treated with RNase-free DNase I (Roche) to remove any residue. DNA. The synthesis of the first strand of cDNA was performed using the (dT) primer, and 2 μί (~1 gg) of the cDNA was subjected to PCR in a 50-μί reaction mixture containing a suitable primer set (see Table ^ for comparison). , WSSV heart and 2〇叩2 (§ The gene fragment was also amplified from the same template by the primer group dnapolF/dnapolR and vp28F/vp28R, respectively. One shrimp million muscle egg 48 1296285 white primer group, muscle The kinesin F1/actin sR1 was used as an internal control for RNA quality and amplification efficiency. To confirm the absence of WSSV DNA contaminants in these RNA samples, a WSSV genomic DNA-specific primer set, IC-F2/IC-R3 (which are regions between five genes derived from the WSSV genome) were also used as a quality control group. These primers were used to amplify the target ORF/gene sequence. It is shown in Table 1. Analysis of very early gene promoters and coding regions According to the genome of WSSV T-1 (NCBI accession number · AF440570), the nucleotide sequences of these ORFs and the upstream region of these ORFs are Use 10 computer programs NNPP (Reese, MG·, EecKman, FH· 1995. New neural network algorithms for improved eukaryotic promotor site recognition. In: The seventh international genome sequencing and analysis conference. Hilton Head Island, SC; MG Reese, et al. (1996), Large scale sequencing 15 specific neural networks for promotor and Splice site recognition. In: Hunter, L., Klein. TE (Eds.), Biocomputing: Proceedings of the 1996 Pacific symposium. World Scientific Publishing, Singapore) and the GenBank/EMBL, SWISSPROT, PIR and EMBOSS databases were analyzed. 20 Π Results The microarray and CHX treatment were used to screen the WSSVIE gene. When the WSSV DNA (ORF/gene) microarray was used to examine viral gene expression, the protein synthesis inhibitor CHX present in WSSV-infected shrimp was It is expected to result in a specific accumulation of 49 1296285 RNA transcripts of very early genes. This is because, although transcription of all other viral genes requires viral proteins as transcription factors, the synthesis of these proteins has been inhibited by the presence of CHX.
圖1顯示,於3個以不同劑量的CHX (12.5 rng/kg、62.5 mg/kg與250 mg/kg)來進行的病毒攻毒試驗中,在^^^感 染相對於假感染(mock infection)的條件下,位在微陣列上 的532個WSSV ORFs的被正規化的Cy3螢光強度(亦即表現 位準)的散佈圖。 各個被繪出的點是根據三重複的微陣列結果,對應於 一個單一的WSSVORF,並且表示Cy3螢光位準相對於β_肌 動蛋白的表現位準的比值。與45。等值線的接近性 (Proximity to the 45。line of equivalence)表示在被感染的與 未被感染的條件下的表現有相似的位準。差異性表現的臨 界線(differential expression cut-off line)(1.5:l)被顯示於圖 1 的C組中。 如自圖1中可以看到的,在有漸增劑量的CHX的存在 下,WSSV基因的差異性表現位準漸增地接近該45。等值 線。所觀察到的結果不僅證實CHX處理成功地抑制病毒蛋 白合成,也暗示對於大多數的這些532個WSSV ORFs而 20言,WSSV基因轉錄確實要依靠一或多種病毒蛋白的存在。 相當地不受最高的CHX劑量所影響(亦即具有一大於 1 · 5:1的差異性表現位準)的orf被認為是IE基因的候選 物。雖然接近於該等散佈圖的初始點的數據點無法被清楚 地辨認’電腦分析從圖1的C組中鑑定出60個IE基因候選物。 50 1296285 CHX-不敏感的基因的阶_代认分析 於上面被鑑定出的60個IE基因候選物被進一步進行 RT-PCR分析。圖2顯示3個WSSV IE基因候選物的〇RFs (ORF126、ORF242、ORF418)的瓊脂糖凝膠電泳RT-pCR結 5 果,其中WSSV DNA聚合酶基因(也叫70/)被用作為一對照 組,被用來擴增標的0RF/基因序列的引子組被列示於表1 中,以及結果是根據從在8 hpi之時的WSSV-感染的蝦的鯨 所萃取出的總RNA。徑1顯示250 mg/kg CHX-預處理組的 RT-PCR結果;徑2顯示載劑-預處理組(只有20%乙醇)的 10 RT-PCR結果;徑3顯示未進行反轉錄反應的250 mg/kg CHX-預處理組的PCR結果;以及徑4顯示從WSSV基因組 DNA擴增出的PCR產物(PCR正對照組);以及徑Μ是100 bp DNAp皆梯(Lambda Biotech Inc.,Taiwan) 〇 所獲得的結果鑑定出3個CHX-不敏感的〇RF,亦即 15 ORF126、ORF242與ORF418。來自不同的個別呢3%感染 的蝦的總RNA樣品的重複查對確認在圖2中所觀察到的該 CHX-不敏感性是一致的。這3個〇rfs在3個已知的〜^¥分 離株的基因組内的可能的序列座標被概述於表4中。可看出 這3個ORFs的任何一個在該3個已知的WSSV分離株中沒有 20 發生刪除。 51 1296285 表4· 3個被鑑定出的CHX-不敏感的ORFs在3個已知的WSSV分 離株基因組内的序列座標 台灣分離株(WSSV T-1)* 泰國分離株** 中國分離株*** NCBI登錄編號 NCBI登錄編號 NCBI登錄編號 AF440570 AF369029 AF332093 ORF126 65711〜66385 81077〜81751 32125〜32799 ORF242 131023〜131349 146706〜146380 97436〜97762 ORF418 242850〜243032 256954〜257136 207904〜208086 *:分離自臺灣被感染的草蝦,它的完整基因組序列被直接地提送至 GenBank來供寄存;以及術語“T-1株,,是於L.-L. d (2獻2), 5 30人j?36-W7中被首次描述。 **:分離自於1996年自泰國進口的被感染的草蝦,參見C.W vim Hulten et al·,Virology· July 20, 2001,286 (1):7-22。 ***:於1996年10月分離自中國東部的廈門市同安區(Tongan,Xiamen,east China)被感染的斑節瑕,參見, j 10 Virol” Dec. 2001,75 (23): 11811-11820 〇 WSSV IE基因候選物的啟動子活性分析 參見圖3,在轉染後72小時之時,由被表現的EGFP (增 強的綠色螢光蛋白質)所產生的綠色螢光訊號被觀察到只 出 現在被 pIZME/WSSV126-lk/V5-EGFP-His 或 15 pIZMEAVSSV126-2k/V5-EGFP-His (這雨個重組型質體被 構築成分別地含有依據本發明的WSSV ORF126的1 kbp與2 kbp啟動子序列)所轉染的sf9細胞,以及在被正對照組質體 (pIZ/V5-EGFP-His)所轉染的 Sf9細胞。 被構築成分別地含有其他兩個WSSV IE基因候選物的 20啟動子序列的質體,亦即piZME/WSSV242/V5-EGFP-His 與卩12八压/\¥83乂418/\^5$0??-耶,在被它們所轉染的8£9 昆蟲細胞内提供負面結果(數據未示出)。 ORF126因而被命名為WSSV W (極早期基因#1)。同樣 驚奇地觀察到:該WSSV 基因的1 kbp與2 kbp啟動子序 25列兩者要比該正對照組質體pIZ/V5-EGFP-His產生更高的 52 1296285 EGFP螢光訊號,該正對照組質體含有昆蟲病毒QpMNPV [貫杉毋蛾核多角體病毒(Orgyia Pseudotsugata multicapsid nucleopolyhedrosis virus)] 基因的啟動子,亦即办正2啟 動子(參見圖3)。在西方墨點分析中也發現到相似的結果(圖 5 4)。另外,在這兩個不同的啟動子活性分析的重複實施中 也觀察到一致的結果(資料未顯示出)。 由圖3也觀察到,無綠色螢光訊號在被質體 ρΙΖΔΙΕ/WSSV126rev/V5-EGFP-His (它被構築成含有 wssv ORF126的1 kbp啟動子序列的反向序列)所轉染的sf9昆蟲 10 細胞中被產生。這個事實暗示該WSSV /el基因的啟動子較 佳地是呈順向方位被可操作地連結至一標的基因。 製作iel轉錄本的5’和y端的圖譜 被選殖至pGEM-T Easy載體内的5,RACE產物的分析 顯示:在7個首先被隨機挑選出的選殖株之中的6個選殖株 15内,5’端是坐落在位於推定的ATG起始密碼子的上游的52 nt (G)處,而在另一個選殖株内,5’端是位在51 nt (τ)處(圖 5)。這暗示-52 nt G代表主要的轉錄起始點。在該轉錄起始 位址的上游(-26 nt)(相對於ATG轉譯起點的-82 nt至-78 nt 處),發現有一個推定的TATA盒(TATAA)。該W推定的轉 2〇錄起始位址的上游序列的NNPP [有關於啟動子預測的中柩 、、罔路(Neural Network for promoter prediction)]分析鐘定出 一個高可能性的被預測的基本啟動子區域是位在推定的轉 譯起始密碼子前方的-92 nt和-43 nt之間(圖5)。 另外,被選殖的3, RACE產物的序列分析顯示聚⑷被 53 1296285 加入在一個位於A AT AAA聚腺苷酸化訊號的下游17 nt處的 位址(圖5)。 圖6顯示一個非常相似的5’ UTR態樣亦被發現存在於 WSSV dnapol基 M (L,L· Chen et al· (2002),Virology 301, 5 136-147),以反 WSSV ηΛ 與 rr2 基舀(M.-F· Tsai et al· (2000),Figure 1 shows that in 3 viral challenge tests with different doses of CHX (12.5 rng/kg, 62.5 mg/kg, and 250 mg/kg), infection was compared to mock infection. A scatter plot of the normalized Cy3 fluorescence intensity (ie, performance level) of the 532 WSSV ORFs located on the microarray. Each of the plotted points is based on a three-repeat microarray result corresponding to a single WSSV ORF and represents the ratio of the Cy3 fluorescence level to the expression level of β_actin. With 45. The proximity of the contour (Proximity to the 45. line of equivalence) indicates a similar level of performance in infected and uninfected conditions. The differential expression cut-off line (1.5:1) is shown in group C of Figure 1. As can be seen from Figure 1, the differential expression level of the WSSV gene is gradually increasing close to the 45 in the presence of increasing doses of CHX. Contour. The results observed not only confirmed that CHX treatment successfully inhibited viral protein synthesis, but also suggested that for most of these 532 WSSV ORFs, the WSSV gene transcription does depend on the presence of one or more viral proteins. Orf, which is considerably unaffected by the highest CHX dose (i.e., having a differential performance level greater than 1 · 5:1), is considered a candidate for the IE gene. Although data points close to the initial points of the scatter plots could not be clearly identified' computer analysis identified 60 IE gene candidates from Group C of Figure 1. 50 1296285 Order of CHX-insensitive genes _ recognition analysis The 60 IE gene candidates identified above were further subjected to RT-PCR analysis. Figure 2 shows the agarose gel electrophoresis RT-pCR junction of 〇RFs (ORF126, ORF242, ORF418) of three WSSV IE gene candidates, in which the WSSV DNA polymerase gene (also called 70/) was used as a control. The group, the primer set used to amplify the target ORF/gene sequence, is listed in Table 1, and the results are based on total RNA extracted from whales of WSSV-infected shrimp at 8 hpi. Path 1 shows RT-PCR results for the 250 mg/kg CHX-pretreatment group; Run 2 shows 10 RT-PCR results for the vehicle-pretreatment group (only 20% ethanol); Trail 3 shows 250 for no reverse transcription reaction PCR results of the mg/kg CHX-pretreatment group; and PCR 4 shows the PCR product amplified from the WSSV genomic DNA (PCR positive control); and the Μ is 100 bp DNAp ladder (Lambda Biotech Inc., Taiwan) The results obtained by 〇 identified three CHX-insensitive 〇RFs, namely 15 ORF126, ORF242 and ORF418. Repeated alignment of total RNA samples from different individual 3% infected shrimps confirmed that the CHX-insensitivity observed in Figure 2 was consistent. The possible sequence coordinates of these three 〇rfs in the genome of three known ~^¥ isolates are summarized in Table 4. It can be seen that none of the three ORFs deleted in the three known WSSV isolates. 51 1296285 Table 4. Sequence coordinates of three identified CHX-insensitive ORFs within the genome of three known WSSV isolates. Taiwan isolate (WSSV T-1)* Thai isolate ** Chinese isolate* ** NCBI registration number NCBI registration number NCBI registration number AF440570 AF369029 AF332093 ORF126 65711~66385 81077~81751 32125~32799 ORF242 131023~131349 146706~146380 97436~97762 ORF418 242850~243032 256954~257136 207904~208086 *:Separated from Taiwan Infected grass shrimp, its complete genome sequence is directly sent to GenBank for storage; and the term "T-1 strain, is in L.-L. d (2 offering 2), 5 30 people j? 36 -W7 was first described. **: Isolated from infected grass shrimp imported from Thailand in 1996, see CW vim Hulten et al., Virology· July 20, 2001, 286 (1): 7-22. **: Infected spotted scorpionfish from Tongan, Xiamen, east China, in October 1996, see, j 10 Virol” Dec. 2001, 75 (23): 11811-11820 The promoter activity analysis of the 〇WSSV IE gene candidate is shown in Figure 3, at the transfection At 72 hours, the green fluorescent signal produced by the expressed EGFP (enhanced green fluorescent protein) was observed to be present only in pIZME/WSSV126-lk/V5-EGFP-His or 15 pIZMEAVSSV126-2k/V5. -EGFP-His (this rain-recombinant plastid is constructed into sf9 cells transfected with the 1 kbp and 2 kbp promoter sequences of WSSV ORF126 according to the present invention, respectively), and in the positive control plastid ( Sf9 cells transfected with pIZ/V5-EGFP-His). The plastids of the 20 promoter sequences, which are respectively constructed to contain two other WSSV IE gene candidates, namely piZME/WSSV242/V5-EGFP-His and 卩12 八压/\¥83乂418/\^5$0 ??- Yeah, providing negative results in the 8£9 insect cells they transfected (data not shown). ORF126 was thus named WSSV W (very early gene #1). It was also surprisingly observed that both the 1 kbp and 2 kbp promoter sequences of the WSSV gene produced a higher 52 1296285 EGFP fluorescence signal than the positive control plastid pIZ/V5-EGFP-His. The plastid of the control group contained the promoter of the insect virus QpMNPV [Orgyia Pseudotsugata multicapsid nucleopolyhedrosis virus] gene, that is, the positive 2 promoter (see Figure 3). Similar results were found in Western blot analysis (Fig. 5 4). In addition, consistent results were observed in the repeated implementation of these two different promoter activity assays (data not shown). It is also observed from Figure 3 that the green-free fluorescent signal is sf9 insect transfected by the plastid ρΙΖΔΙΕ/WSSV126rev/V5-EGFP-His (which is constructed as a reverse sequence of the 1 kbp promoter sequence containing the wssv ORF126). 10 cells are produced. This fact suggests that the promoter of the WSSV /el gene is preferably operably linked to a target gene in a forward orientation. The 5' and y-end maps of the iel transcript were cloned into the pGEM-T Easy vector. Analysis of the RACE product revealed that 6 of the 7 first randomly selected strains were selected. Within 15, the 5' end is located at 52 nt (G) upstream of the putative ATG start codon, while in the other selected strain, the 5' end is at 51 nt (τ) (Fig. 5). This implies that -52 nt G represents the primary transcriptional starting point. Upstream (-26 nt) of the transcription start site (-82 nt to -78 nt relative to the ATG translation start), a putative TATA box (TATAA) was found. The NNPP of the upstream sequence of the putative t-recorded start address [the neural network for promoter prediction] has a high probability of being predicted. The basic promoter region is between -92 nt and -43 nt in front of the putative translation start codon (Figure 5). In addition, sequence analysis of the selected 3, RACE product revealed that poly(4) was added by 53 1296285 at a site located 17 nt downstream of the A AT AAA polyadenylation signal (Figure 5). Figure 6 shows that a very similar 5' UTR pattern was also found in the WSSV dnapol-based M (L, L. Chen et al. (2002), Virology 301, 5 136-147) with anti-WSSV ηΛ and rr2 groups.舀(M.-F· Tsai et al· (2000),
Wro沁277, 92-99)。由於這4個基因的轉錄起始位址均順 應於節肢動物起始要素,亦即(八/<:/1^八(0/1[)1[(1>.(:/1^^ and P· Cherbas (1993),Insect Biochem· Mol· Biol” 23, Sh90),可以合理地推論:這些病毒基因全都具有允許它們 10 藉由至少節肢動物宿主RNA聚合酶II而被轉錄的轉錄基本 要素。 藉由RT:_?CR的ΨSSV iel基因轉錄作用的暫時性分析 一個RT-PCR暫時性分析顯示轉錄本是首先在2 hpi 被偵測到,並且持續到72 hpi均被發現到(圖7)。該PCR 15 產物條帶的強度隨著時間而增加,在18 hpi之時達到最大值 並且之後持績處在一南表現位準下。作為一比較,另外兩 個WSSV基因,也叩W和vp2S [—個WSSV主要外套蛋白質 基因(major envelope protein gene),參見X-/f. L⑼,以 α/. (2005), Λ Ww/·,Am· 2005, 79 (7),以0-以9],的轉錄本直到 20 4 hpi時均未被偵測到。 Π ·討論 病毒的極早期(ΙΕ)基因是在一病毒的初次感染或再活 化之後立即被表現。這群的基因是藉由它們即使在蛋白質 合成抑制劑的存在之下會產生轉錄本的能力而被實驗地界 54 1296285 定出(F.X· Zhu et al· (1999),J· Virol·,73, 5556-5567)。 在本發明中,在以wssv攻毒蝦(草蝦)之前,一個蛋白 合成抑制劑,CHX,被用來預處理該等瑕(草蝦)。蝦被注射 以3個不同劑量的CHX (每kg體重各為12.5、62.5和250 5 mg),而如所預期的,當CHX的劑量被增加時,被表現的 WSSV基因數目被減少(圖1)。然而,於微陣列分析中,即 使是在最高的CHX劑量(250 mg/kg體重,於預先的試驗中, 以這個劑量來處理的未攻毒的蝦只存活歷時大約12小時, 資料未示出)下,仍然有60個產生相當地高數目的轉錄本的 10 WSSV ORFs (圖 1 的c組)。 RT-PCR將IE基因候選物的數目減少到只有3個會一貫 地顯示出CHX-不敏感性(圖2)。就所觀察到的IE基因候選物 的咼初始數目(或偽陽性)的一個可能原因也許是,在活體 内,CHX不能同步地以及完全地抑制每一個細胞内的所有 I5 IE基因的表現,尤其是對於具有一個強啟動子的m基因而 吕。結果,由於任何一個病毒];E基因轉錄因子的出現可能 會立即地觸發下游基因的表現級聯,極有可能遲發早期和 晚期基因的轉錄亦會非常快地開始。 另一方面,參見圖1的C組.,可以注意到,不只是丨5:1 2〇 差異性表現臨界線標準(differential expression cutwff criterion)有點武斷,絕對的表現位準(absolute expression levels)也隨著CHX的劑量漸增而被大大地降低,這使得要 準確地定量螢光強度數據更為困難。因此,可以合理的來 推測·可旎仍存在有未被包含在圖1的C組中所鑑定出的6〇 55 1296285 個候選物内的其他IE基因。 在文獻中曹報導過有數種桿狀病毒極早期基因在病毒 感染過程的早期被表現於一範圍的昆蟲細胞株内,而且通 常是藉由跨越物種的宿主細胞轉錄機制而被轉錄(2λΖλ 5 Hegedus et al· (1998),Gene,207, 241-249·,Y.G· Zhao and Ρ· 五狀/如⑽"999),/fzacf Me?/·价从,S,。因此,IE基因 在宿主範圍的決定上可能是重要的。 就申請人所知,昆蟲細胞株内的WSSV感染尚有待被文 件證實。然而,在本文中被鑑定出的wssv啟動子能夠 10 於非宿主的Sf9細胞中驅動短暫的EGFP表現(圖3)。該WSSV 化7啟動子因此必定共有用於無脊椎動物轉錄因子辨識的守 十亙性序列。 因此,基於該WSSV化1啟動子即使是藉由一個非十足 目動物(non-decapod)宿主的轉錄因子可被活化的事實,可 15 以合理的假設:WSSV能夠感染一廣泛範圍的宿主,甲殼類 以及,可能地,非甲殼類(7:W. (i997), WorM /.Wro沁277, 92-99). Since the transcription initiation sites of these four genes are consistent with the arthropod initiation elements, that is, (eight/<:/1^8 (0/1[)1[(1>.(:/1^^ And P. Cherbas (1993), Insect Biochem·Mol·Biol” 23, Sh90), it can be reasonably inferred that all of these viral genes have transcriptional essential elements that allow them to be transcribed by at least the arthropod host RNA polymerase II. Temporary analysis of ΨSSV iel gene transcription by RT:_?CR A RT-PCR transient analysis showed that the transcript was first detected at 2 hpi and persisted until 72 hpi (Figure 7). The intensity of the PCR 15 product band increases with time, reaching a maximum at 18 hpi and then at a performance level of one. As a comparison, the other two WSSV genes are also And vp2S [- a WSSV major envelope protein gene, see X-/f. L(9), with α/. (2005), Λ Ww/·, Am· 2005, 79 (7), with 0- The transcript of 9] was not detected until 20 4 hpi. Π · The very early (ΙΕ) gene of the virus was discussed at the beginning of a virus. Immediately after infection or reactivation, the genes of this group were identified by the experimental boundary 54 1296285 by their ability to produce transcripts even in the presence of inhibitors of protein synthesis (FX· Zhu et al· (1999) ), J. Virol, 73, 5556-5567). In the present invention, before the challenge of shrimp (grass shrimp) with wssv, a protein synthesis inhibitor, CHX, was used to pretreat the cockroach (grass shrimp) Shrimp were injected with 3 different doses of CHX (12.5, 62.5 and 250 5 mg per kg of body weight), and as expected, when the dose of CHX was increased, the number of expressed WSSV genes was reduced ( Figure 1). However, in the microarray analysis, even at the highest CHX dose (250 mg/kg body weight, the untrained shrimp treated at this dose lasted approximately 12 hours in the previous trial, Under the data, there are still 60 10 WSSV ORFs that produce a fairly high number of transcripts (group c in Figure 1). RT-PCR reduces the number of IE gene candidates to only 3 and consistently displays Out of CHX-insensitivity (Figure 2). Observed IE gene candidates One possible reason for the initial number (or false positive) may be that, in vivo, CHX does not synchronously and completely inhibit the expression of all I5 IE genes in each cell, especially for the m gene with a strong promoter. Lu. As a result, the appearance of any one of the viral gene transcription factors may trigger a cascade of downstream genes, and it is highly probable that the transcription of early and late genes will start very quickly. On the other hand, referring to group C of Fig. 1, it can be noted that not only the 丨5:1 2 〇 differential expression cutwff criterion is somewhat arbitrary, and the absolute expression levels are also As the dose of CHX increases, it is greatly reduced, which makes it more difficult to accurately quantify the fluorescence intensity data. Therefore, it can be reasonably assumed that there are still other IE genes which are not included in the 6〇 55 1296285 candidates identified in the group C of Fig. 1 . In the literature, Cao reported that several very early genes of baculovirus were expressed in a range of insect cell lines early in the process of viral infection, and were usually transcribed by the host cell transcriptional mechanism across species (2λΖλ 5 Hegedus Et al. (1998), Gene, 207, 241-249·, YG· Zhao and Ρ· 五状/如(10)"999), /fzacf Me?/·Price from, S,. Therefore, the IE gene may be important in host-scale decisions. As far as the Applicant is aware, WSSV infection in insect cell lines has yet to be confirmed by the document. However, the wssv promoter identified herein was able to drive transient EGFP expression in non-host Sf9 cells (Figure 3). The WSSV 7 promoter therefore must share a sequela sequence for invertebrate transcription factor recognition. Thus, based on the fact that the WSSV-1 promoter can be activated even by a transcription factor of a non-decapod host, it can be reasonably assumed that WSSV can infect a wide range of hosts, carapace Class and, possibly, non-crustaceans (7: W. (i997), WorM /.
MicrobioL Biotech., 13, 433-442; D.V. Lightner (1996), A handbook of pathology and diagnostic procedures for disease of penaeid shrimp. World Aquaculture Society, Baton Rough, 20 L.A··,C.-F· Lo, et al· (1996),Dis· Aquat· Org·,27, 215-225)。 有關另外兩個被鑑定出的CHX-不敏感的基因,亦即 ORF242與ORF418 (它們的啟動子在被轉染的Sf9細胞中無 法驅動EGFP的表現),我們推論某些其他的特定轉錄因子可 能是這兩個IE基因候選物的啟動子要行使功能所需要的。 56 1296285 這些因子據推測是十足目動物的,並且不存在於Sf9細胞 中。這兩個候選物可能是具蝦細胞特異性的,而因此應該 在被排除是屬IE基因之前於蝦細胞内來進行分析。 TATA要素是許多桿狀病毒早期啟動子的主要調節要 5 素,並且是由一個位在轉錄起始子上游的25〜31核苔酸處的 富含 Α/τ的要素所組成(G.W· Blissard and G.F. Rohnnarm (1991),J,Virol·,65,5820-5827\ G.W· Blissard et cil. (1992) Virology,190,783-793·,J.A. Dickson and P.D· Friesen (1991),J· Virol·,65, 4006-4016·,L.A· Guarino and M.W· 10 Smith (1992),J· Virol·,66, 3733-3739·,S.S. Pullen and P.D· Friesen (1995),J. Virol” 69, 156-165)。該 TATA要 I 與轉錄 起始子合起來是RNA聚合酶II啟動子的基本要素。 該WSSV 啟動子區域亦順應這個態樣(圖5),這暗 示:如同大多數的昆蟲桿狀病毒早期基因,WSSV 轉錄 15是由宿主RNA聚合酶Η所媒介。圖6顯示WSSV^^/、rrj? 和rr2亦順應這個態樣。它們的轉錄起始位址相符於 CAGT/CAGT相關的要素(U· C/ze/i α/· (2002),MicrobioL Biotech., 13, 433-442; DV Lightner (1996), A handbook of pathology and diagnostic procedures for disease of penaeid shrimp. World Aquaculture Society, Baton Rough, 20 LA··, C.-F· Lo, et al · (1996), Dis· Aquat· Org·, 27, 215-225). For the other two identified CHX-insensitive genes, ORF242 and ORF418 (their promoters are unable to drive EGFP in transfected Sf9 cells), we conclude that some other specific transcription factors may It is required for the promoters of these two IE gene candidates to function. 56 1296285 These factors are presumed to be decapods and are not present in Sf9 cells. These two candidates may be shrimp-cell specific and should therefore be analyzed in shrimp cells before being excluded from the IE gene. The TATA element is a major regulator of many baculovirus early promoters and consists of a Α/τ-rich element at 25~31 nuclear oxalic acid upstream of the transcriptional promoter (GW· Blissard). And GF Rohnnarm (1991), J, Virol, 65, 5820-5827\ GW· Blissard et cil. (1992) Virology, 190, 783-793, JA Dickson and PD·Friesen (1991), J. Virol· , 65, 4006-4016·, LA· Guarino and MW· 10 Smith (1992), J. Virol·, 66, 3733-3739·, SS Pullen and PD· Friesen (1995), J. Virol” 69, 156- 165) The TATA combination of I and the transcriptional initiator is an essential element of the RNA polymerase II promoter. The WSSV promoter region also conforms to this pattern (Fig. 5), suggesting that, like most insect rods The early viral gene, WSSV transcription 15 is mediated by host RNA polymerase. Figure 6 shows that WSSV^^/, rrj? and rr2 also conform to this pattern. Their transcription initiation sites are consistent with CAGT/CAGT related elements. (U·C/ze/i α/· (2002),
301,136-147\ L· Cherbas and Ρ· Cherbas (1993),Insect Biochem· Mol· Biol” 23,81-90·,S.S· Pullen and P.D. Friesen 2〇 "995),X VzroZ·,69, 3575-35S3),並且它們是位於該TATA 盒下游的25至28個核苷酸處。這暗示這3個基因應該也是藉 由宿主RNA聚合酶II而被轉錄。然而,這些全被chx處理 所抑制的基因在轉染分析中並未被表現(關於如叩,參見 圖3,而關於rd和rr2,資料未示出)。因此推測:、 57 1296285 r"和rr2的成功轉錄需要有病毒蛋白質轉錄因子(無論是除 了 RNA聚合酶II所用的宿主轉錄因子之外,或是作 聚合酶II所用的伯主轉錄因子的一個替代物)的存在。 啟動子活性分析的結果(圖3)暗示該W S S V化J編碼區 5域的上游的序列在sf9細胞内活化基因的表現是非常有效 的。如由圖8可看到的,的5, UTR (未轉譯區域)包含數 個序列是符合於GATA要素(A/T)GATA(G/A)的共有序列。 這可能是重要的,因為該GATA要素被確認是轉錄因子的一 個結合位址,例如在桿狀病毒OpMNPV IE基因,從料,的 10 敗動子内(Ρ·Η· Kogan and G.W. Blissard (1994),J· Virol 68, 813-822)。 圖8亦顯示數個其他可能的調節要素,包含:2個直接 重複序歹丨J(CACACACA與CTCTCTCTCT)、2個短序列的重 複(TTTCTGG與CCAGAAA)、桿狀病毒早期基因啟動子要 15 素(上游調節要素)(CGTGC)〇R.L.丹 (2肌?),/· G^z· Wro/·,抑(Ti 7),」S27dS42)、桿狀病毒晚期 啟動子起始子(TTAAG)(L.A. M. W. (1990),Virology,179,1-8·,T.D. Morris and L.K· Miller301,136-147\ L· Cherbas and Ρ· Cherbas (1993), Insect Biochem· Mol· Biol” 23,81-90·, SS· Pullen and PD Friesen 2〇"995), X VzroZ·, 69, 3575-35S3), and they are located 25 to 28 nucleotides downstream of the TATA box, suggesting that these three genes should also be transcribed by host RNA polymerase II. However, these are all chx treatment sites. The suppressed genes were not expressed in the transfection assay (for eg 叩, see Figure 3, and for rd and rr2, the data are not shown). Therefore, it is speculated that: 57 1296285 r" and rr2 require successful transcription of viral proteins. The presence of a transcription factor (whether in addition to the host transcription factor used by RNA polymerase II or a substitute for the primary transcription factor used by polymerase II). The results of the promoter activity assay (Figure 3) suggest that The sequence upstream of the WSSV-J coding region 5 domain is very efficient in the expression of activating genes in sf9 cells. As can be seen from Figure 8, 5, UTR (untranslated region) contains several sequences that are compatible with GATA. Consensus sequence of element (A/T) GATA (G/A). This can be important because the GATA element is identified as a binding site for the transcription factor, for example, within the baculovirus OpMNPV IE gene, from the 10 dynamometers (Ρ·Η·Kogan and GW Blissard (1994) , J. Virol 68, 813-822. Figure 8 also shows several other possible regulatory elements, including: 2 direct repeats 歹丨J (CACACACA and CTCTCTCTCT), 2 short sequence repeats (TTTCTGG and CCAGAAA) The baculovirus early gene promoter requires 15 elements (upstream regulatory elements) (CGTGC) 〇 RL Dan (2 muscles?), /· G^z· Wro/·, (Ti 7), “S27dS42), rod-shaped Viral late promoter promoter (TTAAG) (LAMW (1990), Virology, 179, 1-8·, TD Morris and LK· Miller
Gmg 7扣,747453),以及一個可產生有如一轉錄增 2〇 強子的功能的迴文序列(palindromic sequence)(C.r. McMurray et al· (1991),Proc· Natl· Acad· Sci· USA·,88, 666-670; C. Rasmussen et aL (1996), Virology, 224, 235-245) 〇 特別地,由於該迴文序列是坐落在轉譯起始位址的上 58 1296285 游1,000 nt更遠之處,它可能有助於解釋 pIZME/WSSV126-2k/V5-EGFP-His 與 pIZME/WSSV126-lk/V5-EGFP-His在被轉染的Sf9細胞内的表現位準之間的 差異(圖3)。 5 在另一方面,在由處於24 hpi之時的WSSV-感染的蝦所 萃取出的RNA上所進行的5, RACE分析沒有產生證據來顯 示TTAAG桿狀病毒晚期啟動子起始子曾有產生有如一用 於WSSV id轉錄的起始子的功能。 最後 ’ GenBank/EMBL、SWISSPROT與HR資料庫的 10 BLAST分析預測該化7編碼區域含有Cys2/His2型鋅指要素 (Cys2/His2-type Zinc finger m〇Uf)。這個要素在DNA結合上 具有一角色,並且暗示化7是產生有如一轉錄因子的功能。 進步的研究應探討有那些wssv基因是使用W作為一轉 錄因子。 於本木°兒明書内所弓1用的所有專利與文獻資料以及當 •參Γ娘以它們的整體在此被併入本案以作 内m佔1風。。咖物㈣,本⑽剛(包含界定在 20 的㈣已就它料定《例來作說明,可瞭解到 的疋,它可以作進一+沾作 啄肿巧 涵蓋本發明的任何變並且本件”案被欲求能 本發明的原㈣包含M、/纽造物,它料常是遵循 實施方式而且可被… 本發明所屬技藝中的慣用 以及落在了 ^ 以上所描述的必要特徵的變更, 在下面隨文檢附的申請專利範圍的射内。 59Gmg 7 deduction, 747453), and a palindromic sequence that produces a function like a transcriptional increase of 2 protons (Cr McMurray et al. (1991), Proc. Natl. Acad. Sci. USA, 88, 666-670; C. Rasmussen et aL (1996), Virology, 224, 235-245) 〇 In particular, since the palindromic sequence is located at the translation start address of 58 1296285, swim 1,000 nt more Farther, it may be helpful to explain the difference between the expression levels of pIZME/WSSV126-2k/V5-EGFP-His and pIZME/WSSV126-lk/V5-EGFP-His in transfected Sf9 cells ( image 3). 5 On the other hand, the 5, RACE analysis performed on RNA extracted from WSSV-infected shrimp at 24 hpi did not produce evidence to show that the TTAAG baculovirus late promoter promoter was produced. It is like a function for the initiator of WSSV id transcription. Finally, the 10 BLAST analysis of the GenBank/EMBL, SWISSPROT and HR databases predicted that the 7 coding region contained the Cys2/His2-type Zinc finger m〇Uf. This element has a role in DNA binding and suggests that 7 is capable of producing a transcription factor. Progressive research should explore the use of W as a transcription factor for those wssv genes. All the patents and literature materials used in the bow of the book in the book, and in the case of the Γ Γ Γ 以 以 以 以 以 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 . Coffee (4), Ben (10) just (including the definition of (4) defined in 20, it is intended to be described as an example, which can be understood, it can be made into a + 沾 啄 啄 涵盖 涵盖 涵盖 涵盖 涵盖 涵盖 涵盖 涵盖 涵盖 涵盖 ” ” ” ” ” ” The original (four) of the present invention is intended to contain M, / New Zealand, which is often followed by the embodiment and can be used by the art to which the present invention pertains and changes in the essential features described above. The scope of the patent application scope attached to the document inspection. 59
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW94100625A TWI296285B (en) | 2005-01-10 | 2005-01-10 | Promoter sequences from wssv immediate early genes and their uses in recombinant dna techniques |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW94100625A TWI296285B (en) | 2005-01-10 | 2005-01-10 | Promoter sequences from wssv immediate early genes and their uses in recombinant dna techniques |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200624555A TW200624555A (en) | 2006-07-16 |
| TWI296285B true TWI296285B (en) | 2008-05-01 |
Family
ID=45068715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW94100625A TWI296285B (en) | 2005-01-10 | 2005-01-10 | Promoter sequences from wssv immediate early genes and their uses in recombinant dna techniques |
Country Status (1)
| Country | Link |
|---|---|
| TW (1) | TWI296285B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI670373B (en) * | 2011-02-08 | 2019-09-01 | 淡馬錫生命科學實驗室有限公司 | A novel expression cassette for efficient surface display of antigenic proteins |
-
2005
- 2005-01-10 TW TW94100625A patent/TWI296285B/en not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI670373B (en) * | 2011-02-08 | 2019-09-01 | 淡馬錫生命科學實驗室有限公司 | A novel expression cassette for efficient surface display of antigenic proteins |
Also Published As
| Publication number | Publication date |
|---|---|
| TW200624555A (en) | 2006-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Microarray and RT-PCR screening for white spot syndrome virus immediate-early genes in cycloheximide-treated shrimp | |
| Rout et al. | DNA vaccines encoding viral envelope proteins confer protective immunity against WSSV in black tiger shrimp | |
| CN108276486B (en) | Cat ω2 interferon mutant and preparation method and application thereof | |
| CN109134669B (en) | Fusion protein of porcine pseudorabies virus, preparation method, application and vaccine thereof | |
| CN104059927B (en) | Preparation method and product of chicken Newcastle disease glycoprotein virus antigen | |
| WO2010118205A2 (en) | Production of an intact virus in a mammalian (non-host) cell system using a secondary non-host viral construct | |
| CN110066769B (en) | Avian cells for improved virus production | |
| CN111825768A (en) | Based on self-assembled ferritin nanoantigen particles and influenza vaccine and preparation method | |
| CN112442131A (en) | Self-assembly ferritin-based nano antigen particle, infectious bursal disease vaccine prepared from self-assembly ferritin-based nano antigen particle and application of infectious bursal disease vaccine | |
| CN111647087B (en) | Chimeric virus-like particle vaccine and preparation method and application thereof | |
| TWI296285B (en) | Promoter sequences from wssv immediate early genes and their uses in recombinant dna techniques | |
| US7429480B2 (en) | Promoter sequences from WSSV immediate early genes and their uses in recombinant DNA techniques | |
| CN106916824A (en) | Citrus fruit fly Taiman genes and its variable sheer body detecting method and its dsRNA | |
| WO2023278797A1 (en) | Engineered nodaviral cargo delivery systems | |
| CN112321718B (en) | Self-assembly ferritin-based nano antigen particle, peste des petits ruminants vaccine and preparation method and application thereof | |
| CN110669142A (en) | RGD-fused porcine circovirus type 2 virus-like particle, mutant infectious clone, preparation method and application thereof | |
| CN110066827B (en) | Recombinant baculovirus transfer vector containing porcine pseudorabies virus gB protein gene, recombinant baculovirus and preparation method and application | |
| CN110408602B (en) | PCV2-PRRSV recombinant virus, and preparation method, gene, application and vaccine thereof | |
| CN108374003A (en) | Migratory locusts Protein-tyrosine-phosphatase PTP1B and its encoding gene and application | |
| KR102138938B1 (en) | Beculovirus-based Gene Transducer Including Influenza-induced Cell-Invesive Peptide | |
| CN109295014B (en) | A kind of atypical swine fever virus E2 protein recombinant baculovirus and its preparation method and application | |
| CN108840921B (en) | Sheep alpha interferon mutant and preparation method and application thereof | |
| CN104761624A (en) | Preparation method and product of chicken infectious bursal disease virus antigen | |
| CN114107176A (en) | CHO cell line for stably expressing African swine fever CD2v protein and construction method and application thereof | |
| CN116143940B (en) | Oral vaccine against carp spring viremia virus, its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |